Preliminary Regulatory Impact Analysis and Initial Regulatory Flexibility Analysis of the Proposed Rules to Ensure the Safety of Juice and Juice Products

Federal RegisterMay 1, 1998

Ask Donna

What actually matters in this document.

Text

SUMMARY: The Food and Drug Administration (FDA) is publishing the

preliminary regulatory impact analysis (PRIA) that it has prepared

under Executive Order 12866 and initial regulatory flexibility analysis

(IRFA) that it has prepared under the Regulatory Flexibility Act (RFA),

as amended by the Small Business Regulatory Enforcement and Fairness

Act (SBREFA), on the costs and benefits of FDA's proposed regulations

regarding the Hazard Analysis Critical Control Points (HACCP) and

labeling for juice and juice products. FDA is issuing those proposals

because of recent outbreaks of foodborne illness and deaths caused by

consumption of juice products that were not pasteurized or otherwise

processed to control pathogenic microorganisms. Those proposals are

intended to ensure that juice and juice products are safe.

DATES: Submit written comments by May 26, 1998 on aspects of this

analysis related to labeling for juice and juice products and by July

8, 1998 on aspects of this analysis related to HACCP for juice and

juice products.

ADDRESSES: Submit written comments to the Dockets Management Branch

(HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23,

Rockville, MD 20857. Comments should be identified with the docket

numbers found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: David J. Zorn, Center for Food Safety

and Applied Nutrition (HFS-726), Food and Drug Administration, 200 C

St. SW., Washington, DC 20204, 202-205-4729.

SUPPLEMENTARY INFORMATION:

Table of Contents

I. Background

II. Introduction

III. Factors Considered in Developing This Analysis

IV. Regulatory Options

V. Benefits

VI. Costs

VII. Summary of Benefits and Costs

VIII. Initial Regulatory Flexibility Analysis

IX. References

X. Request for Comments

I. Background

This document constitutes FDA's PRIA and IRFA of the proposed rules

to amend the food labeling regulations and to require HACCP for juice

and juice products. Because the industries affected by both proposed

rules substantially overlap and because both proposals address the same

public health problem, the safety of juice and products containing

juice, the agency has chosen to analyze the economic impact of both

proposed rules in a single PRIA and IRFA. These documents analyze both

the costs and benefits of the proposed rules as well as the expected

impacts on the affected small entities. FDA has found that these rules

may constitute significant rules under Executive Order 12866 because

they could have a significant impact on one sector of the economy

(producers of minimally processed juice). In addition, FDA has

determined under the RFA that each proposal would present a significant

impact on a substantial number of small entities.

II. Introduction

FDA has examined the impacts of these proposed rules under

Executive Order 12866. Executive Order 12866 directs Federal agencies

to assess the benefits and costs of available regulatory alternatives

and, when regulation is necessary, to select regulatory approaches that

maximize net benefits (including potential economic, environmental,

public health and safety effects; distributive impacts; and equity).

Under the Executive Order, a regulatory action is ``significant'' if it

meets any one of a number of specified conditions, including having an

annual effect on the economy, competition, or jobs, or if it raises

novel legal or policy issues. FDA finds that each of these proposed

rules may constitute a significant regulatory action as defined by

Executive Order 12866, as discussed as follows.

In addition, FDA has determined that these rules are not

significant rules under the Unfunded Mandates Reform Act of 1995 (UMRA)

requiring benefit-cost and other analyses. Under UMRA significant rule

is defined as ``a Federal mandate that may result in the expenditure by

State, local and tribal governments in the aggregate, or by the private

sector, of $100,000,000 (adjusted annually for inflation) in any 1

year''.

Finally, in accordance with the SBREFA, the Administrator of the

Office of Information and Regulatory Affairs of the Office of

Management and Budget (the Administrator) has determined that these

proposed rules are major rules for the purpose of congressional review.

A major rule for this purpose is defined as one that the Administrator

has determined has resulted or is likely to result in an annual effect

on the economy of $100 million or more; a major increase in costs or

prices for consumers, individual industries, Federal, State, or local

government agencies, or geographic regions; or significant adverse

effects on competition, employment, investment, productivity,

innovation, or on the ability of U.S.-based enterprises to compete with

foreign-based enterprises in domestic or export markets.

III. Factors Considered in Developing This Analysis

This analysis estimates costs and benefits for two proposed

regulations, published in the Federal Register of April 24, 1998 (63 FR

20450 and 20486), that would affect the safety of juice products. The

first rule requires warning statements on minimally processed packaged

juice. That is, juice that has not been processed in a manner that will

produce, at a minimum, a 5-log reduction, for a period at least as long

as the shelf life of the product when stored under normal and moderate

abuse conditions, in the pertinent microorganism. The ``pertinent

microorganism'' is the most resistant microorganism of public health

significance that is likely to occur in the juice. In the remainder of

this analysis, this will be referred to as the ``5-log reduction.''\1\

The second rule requires manufacturers of most juice to implement a

HACCP program with the same 5-log reduction performance criteria.

However, FDA is proposing to exempt retailers who, for the purposes of

this rule, the agency has tentatively decided will include very small

businesses that make juice on their premises and whose total sales of

juice and juice products do not exceed 40,000 gallons per year and who

sell directly to consumers or directly to consumers and other

retailers.

---------------------------------------------------------------------------

\1\ That is, the total combined effect of all controls have the

effect of reducing the number of colony forming units (cfu's) by a

factor of 100,000. This implies that even if the product should

contain 1,000 cfu's per gallon (gal.) prior to processing, the final

product after processing would contain only .01 cfu's per gal.

---------------------------------------------------------------------------

The effective date for the labeling rule is proposed to be 60 days

following publication of the final rule with

[[Page 24255]]

warning statements required either on the labels or, in the case of

products which do not bear the warning statement on the label, on

labeling (e.g., on signs or placards at the point of sale) on juices

that have not been processed in a manner that will produce, at a

minimum, a 5-log reduction. Packaged juices produced by large firms are

required to bear warning labels beginning on January 1, 2000, and

packaged juices produced by small and very small firms\2\ are required

to bear warning labels beginning on January 1, 2001. The agency expects

that the HACCP rule, because of its complexity, will not be finalized

for at least 1 year following finalization of the juice labeling rule.

The HACCP rule is proposed to be effective for large firms, 12 months

following publication of the final HACCP rule; for small firms, 24

months following publication of the final HACCP rule; and for very

small firms, 36 months following publication of the final HACCP rule.

For purposes of this rule, the agency is proposing to define large

processors as those who have more than 500 employees, small processors

as those who have less than 500 employees and very small processors as

those who have either: (1) Total annual sales of less than $500,000, or

(2) that have total annual sales of greater than $500,000 but total

annual food sales of less than $50,000, or (3) that employ fewer than

100 full-time equivalent employees and annually sell less than 100,000

units of the juice in the United States.

---------------------------------------------------------------------------

\2\ The labeling rule does not define ``very small firms'' but

the HACCP rule does give a separate definition of ``very small

firms'' as a subset of ``small firms'' as defined in the labeling

and HACCP rules. Therefore, the term ``very small firms'' has been

used here in relationship to the labeling rule to make clear where

this subset fits in the context of both of these rules. The HACCP

rule defines small businesses as those with fewer than 500

employees. It defines very small businesses as those with total

annual sales of less than $500,000 or those with total annual food

sales of less than $50,000 or those with fewer than 100 employees

and less than 100,000 units of juice sold annually.

---------------------------------------------------------------------------

To a large extent, benefits and costs will depend on how processors

of juice who do not currently implement controls sufficient to achieve

a 5-log reduction respond to the warning label regulation. That is,

firms will choose whether to display the warning statement or to comply

early with the 5-log reduction. The agency has no information to

indicate the choices that specific processors will make.

The actual choice that each processor will make depends on several

factors: (1) The revenue that processors expect to lose because of

consumers' responses to the Government's announcement of the rules and

the warning label, (2) the costs of and length of time allowed to make

label changes, (3) the costs of achieving a 5-log reduction in

pathogens, and (4) the revenue that processors expect to lose if

consumers respond negatively to the changes in product characteristics

caused by processing the juice.

Processors will choose to discontinue juice production if they

perceive that either labeling or a change in processing practices will

lower profits below a ``normal'' return.\3\ In other words, processors

will go out of the juice business rather than comply with these

regulations only if one of the two following conditions is satisfied:

(1) The combination of the cost of displaying the warning labeling and

the reduction in revenue caused by the negative response of consumers

to the warning results in below normal profits; or (2) a combination of

increased costs from processing and a reduction in revenue caused by

the negative response of consumers to the changes in product quality

results in below normal profits.

---------------------------------------------------------------------------

\3\ A normal return on profits is the average market return on

capital that a processor could receive, for example, by investing in

the stock market.

---------------------------------------------------------------------------

For the purposes of this analysis, the agency has assumed that, in

order to avoid having their products associated with the warning to

consumers, all establishments that will eventually be covered by the

HACCP rule will implement controls sufficient to achieve a 5-log

reduction when the labeling rule takes effect. The agency has also

assumed for the purposes of this analysis that those establishments not

covered by the HACCP rule will display the warning statement for

packaged juice products. However, in order to avoid displaying the

warning statement, these establishments may choose to process their

juice in a manner sufficient to achieve a 5-log reduction in pathogens

or under an adequate voluntary HACCP plan.

IV. Regulatory Options

The preambles in the accompanying proposed regulations describe the

compelling public need for these regulations. For example, in recent

years, pathogens have been discovered in fresh juices after having

caused severe illness in humans. These products were previously not

known to be vehicles for such hazards, given their low pH. Because

these events have occurred, the agency tentatively finds that it is

prudent to require the adoption of preventative controls for hazards

now associated with juice where controls may not have been previously

thought to be necessary.

There are a number of regulatory options that FDA has preliminarily

considered to reduce the risks associated with consuming juice

products. FDA requests comments on benefits, costs, and any other

aspect of these options.

A. Take No New Regulatory Action

Choosing this option would imply either reliance on: (1) Existing

Federal regulation, (2) State and local regulatory activity, (3)

business interests, (4) consumer demands, and (5) product liability

pressures to reduce risks incurred by consumers of juice products or

acceptance that the risks that juice currently presents are risks that

consumers are unwilling to pay to reduce. In the first case, it is

unlikely that the market will adjust to eliminate the risks present in

juice because of the difficulty of establishing the link between the

various kinds of illnesses, whether acute or chronic, to consumption of

juice. Generally, this link may only be established when there are

large, geographically focused outbreaks of acute illness. However,

research indicates that most cases of foodborne illness are sporadic

and geographically dispersed and not associated with any identifiable

and focused outbreaks (Ref. 1). In the second case, it is presumed that

consumers are willing to pay to reduce these risks given the sizeable

estimated benefits of the proposed rules. Finally, while industry and

State governments have undertaken steps in many areas to reduce risks

associated with juice, FDA believes that the changes have been made

with the expectations of Federal regulation. It is unlikely that the

market would fully adjust to reduce the risk without additional Federal

action.

B. Regulate Only High-Risk Juice Products or High-Risk Hazards

FDA could choose to make these rules applicable only to juice

products that have been associated by epidemiology or by inspection

history with health hazards. This option is discussed in the appendix

supporting this analysis (Ref. 9). In the appendix, the agency

concluded that unpasteurized or otherwise nonheat treated juices

present the largest risk to consumers because pathogens pose the

highest risk of the several categories of hazards. FDA is proposing

that all chemical, physical, and biological hazards be included under

HACCP, despite the differences in relative risk posed by different

types of hazards. It is important to note that processors may, under

the umbrella of

[[Page 24256]]

HACCP, adjust for the probability and severity of hazards by adjusting

critical limits, the frequency of monitoring, intensity of corrective

action, or any number of other margins. FDA has not evaluated the

benefits and costs of structuring HACCP based on this option, and seeks

comments on it, especially on the option of covering only some types of

juice.

C. Do Either One of the Proposed Rules but Not Both

One option would be to eliminate the HACCP requirement for juices,

one of the two proposed actions, and only require that juices that are

not processed to achieve a 5-log reduction be labeled with a warning to

consumers. The purpose of this labeling is to alert consumers who are

at increased risk to avoid these products and to inform all consumers

of the risk of these products relative to other juices. However, it is

difficult to predict what products consumers would switch to once they

encounter the warnings. It is possible that some consumers may reduce

their health status by choosing less nutritious substitutes in order to

avoid the products with the warning labels. Although labeling may be

effective for changing both producer behavior (particularly to avoid

displaying the warning) and consumer behavior, the agency believes that

labeling alone is unlikely to be sufficient to address all health

hazards associated with consumption of juice products.

Another option would be to eliminate the labeling rule and only

require that juice processors implement HACCP. This option would reduce

the possibility that some consumers might overreact and avoid all

juice. This option would also allow fresh juice to be marketed without

warnings and would result in some cost savings for products that will

not need to pay for labeling costs. However, it would also result in

some reduction in benefits because the HACCP rule will take longer to

implement than the labeling rule and because the proposed labeling rule

covers juice made at the point of sale and the proposed HACCP rule does

not cover retailers.

D. Require New Current Good Manufacturing Practices

FDA could develop and require current good manufacturing practices

(CGMP's) or sanitation standards specific to juice products to improve

the safety of juices. The use of CGMP's would assist processors in

ensuring the safety of their juices by providing guidance on how to

reduce insanitary manufacturing practices and on how to protect against

food becoming contaminated. While FDA currently has general CGMP's that

provide guidance to all food processing industries, it does not have

specific CGMP's for the juice industry.

There are three reasons that this alternative alone may be

undesirable. First, CGMP's by themselves are unlikely to have a

sufficient impact on the safety of juice, particularly relative to

HACCP. That is, CGMP's do not provide: (1) A structure for each

processor to align specific hazards unique to the processor's

operations with specific control measures; (2) assurance that the

processor will establish specific performance standards appropriate to

the processor's unique operation; (3) records that document that the

performance standards are met; and (4) records of frequent audits to

verify that controls are being applied, all of which are associated

with HACCP. Identifying specific hazards, designing controls that are

specific and unique to each operation, and verifying that these

controls are being applied as specified are essential elements of a

control program that will provide an improved level of food safety.

Secondly, under the HACCP approach being proposed, the industry is

required to use FDA's general CGMP's in part 110 (21 CFR part 110) and

to develop and adopt sanitation standard operating procedures (SOP's)

as part of their prerequisite programs for their HACCP plan. Therefore,

the HACCP approach builds on the foundation of CGMP's at the same time

it avoids the limitations of this alternative.

HACCP is designed for use in all segments of the food industry from

growing, harvesting, processing, manufacturing, distributing, and

merchandising to preparing food for consumption. Prerequisite programs

such as current good manufacturing practices (CGMP's) are an essential

foundation for the development and implementation of successful HACCP

plans.

The production of safe food products requires that the HACCP system

be built upon a solid foundation of prerequisite programs. Each segment

of the food industry must provide the conditions necessary to protect

food while it is under their control. This has traditionally been

accomplished through the application of CGMP's. These conditions and

practices are now considered to be prerequisite to the development and

implementation of effective HACCP plans. Prerequisite programs provide

the basic environmental and operating conditions that are necessary for

the production of safe, wholesome food.

E. Require Pasteurization

FDA could require that all juice be pasteurized rather than

requiring HACCP with a specified 5-log reduction. Although FDA is not

currently aware of other practical methods to achieve this level of

control, solely requiring pasteurization would inhibit new

technological innovation and it would only address one type of hazard

(pathogens that are not heat resistant). In this analysis, the agency

has, in fact, evaluated the costs of pasteurization for those juices

not now pasteurized. It should be pointed out that, by volume, the vast

majority of juices are now pasteurized or otherwise equivalently

treated. Thus, the marginal costs and benefits of requiring

pasteurization only apply to the small fraction of juice that is not

heat treated.

The agency requests comment on the appropriateness of the 5-log

reduction performance standard and if other approaches, such as

establishing a minimal acceptable risk standard for juices, could be

used that would ensure the safety of the juice. The agency requests

comments on what such a minimal acceptable risk standard should be and

how it would be implemented. The agency also invites interested persons

to submit scientific data concerning the acceptability of a 5-log

reduction requirement or whether a more or less stringent performance

standard (e.g., 3- or 7-log reduction) for specific juices would be

more appropriate or whether different approaches consistent with a

minimal acceptable risk standard for juices might be appropriate for

specific juices based on their unique characteristics.

F. Set Different Performance Standards for Processing of Different

Products

One regulatory option would be to establish different performance

standards for processing different types of juice products to decrease

the number of pathogens. In the proposal, the agency has tentatively

proposed that any combination of processing steps which cumulatively

result in a 5-log (a 100,000-fold) reduction in pathogens should be

applied to the production of all types of juice. However, different

products may warrant different processing stringencies because of a

number of factors, including: (1) The initial microbial counts on raw

produce are likely to vary, (2) different types of produce are likely

to harbor different kinds of pathogens, and (3) different products

provide different environments for microbial growth. This

[[Page 24257]]

option could either be exercised as part of the final rule in response

to comments or the proposed standards could remain with the option to

further petition the agency for a different standard. The benefits and

costs of the standard will vary directly with the stringency of

different performance standards. However, FDA does not have data to

estimate preliminarily the costs and benefits of this option.

G. Expand HACCP Rule Coverage

FDA has tentatively concluded that the retail sector should not be

included in the HACCP rule and has asked for comments on the

appropriateness of this conclusion. The expansion of coverage of the

HACCP rule to include retailers that process juice at the point of sale

would add an estimated additional 14,300 restaurants and 1,300 grocery

stores and supermarkets for a total of approximately 16,000

establishments. If the cost for these establishments to implement HACCP

was equivalent to that of very small processors who would be required

to initiate pasteurization ($26,000 in the first year and $11,900 in

subsequent years), then the total additional cost of this option would

be approximately $416 million in the first year and approximately $190

million in subsequent years. However, the agency does not have direct

information about the cost of implementing HACCP in a retail setting

for juice and the actual costs may vary significantly from these

estimates.

H. Use of One of Various Alternatives

An alternative approach to mandating HACCP would be to provide a

more flexible array of options tailored to the microbial risk present

in the particular juice. Manufacturers of apple cider would be provided

a permanent option choosing between labeling or implementing a HACCP

program with a 5-log pathogen reduction. All juices other than

untreated apple cider would be provided a permanent option of choosing

between labeling, implementing a HACCP system, or achieving a 5-log

pathogen reduction. However, FDA believes that this option provides

only weak incentives for processors to implement a HACCP system.

Processors could label hazardous products without taking steps to

improve the safety of juice or choose to achieve a 5-log reduction for

microbial pathogens without addressing other hazards. The agency

believes that labeling would not achieve the same level of product

safety. Additionally, there would be less incentive for processors to

implement a HACCP system, which includes, among other things,

developing and implementing sanitation SOP's and recordkeeping at

critical control points in addition to achieving a 5-log reduction.

Other hazards that would not be addressed include chemical

contaminants, hazardous metals, including lead and tin, mycotoxins,

pesticides, and physical hazards, such as glass.

Another regulatory option would be to include labeling for

unpackaged juice products for all retail outlets, such as restaurants.

This option would also require any very small retailer (as defined for

the purposes of this rulemaking) who is manufacturing less than 40,000

gallons of juice per year and selling it directly to consumers and

other retailers to either label or achieve a 5-log kill until a

requirement for HACCP would become effective 36 months from the date of

publication of the final rule.

If this option is combined with both proposed rules, FDA has

estimated the benefits to be $383 to $478 million annually and

estimated the costs in the first year to be $54 million and the costs

in subsequent years to be $28 million.

V. Benefits

This analysis provides estimates of three additive, independent

benefits of these two proposed rules: (1) Reduced expenditures related

to regulatory enforcement, (2) reduced adverse health effects, and (3)

other benefits. To some extent, the benefits of the two rules are

intertwined. Because of the earlier compliance dates, the impact of the

labeling rule will be to achieve some of the benefits faster. That is,

if firms choose to achieve a 5-log reduction through their processing

practices to avoid labeling, then some of the future benefits that

would be otherwise achieved under HACCP will be achieved sooner because

of the incentive provided by the labeling rule. Also, if at-risk

consumers avoid unpasteurized juices as a result of the labeling, there

will be reduced adverse-health effects prior to the introduction of

HACCP. On average, the labeling rule will achieve some of the benefits

2 years faster than the HACCP rule.

A. Enforcement Benefits

To the extent that these proposed rules are effective at reducing

contaminated juice, they should reduce the number of safety-related

enforcement actions (for both domestic and imported products) taken by

the agency for juice products. The enforcement activities chosen as a

baseline for juice products fall between the period 1992 and 1996

(inclusive) and involve import detentions and domestic recalls.

In the final regulatory impact analysis for FDA's seafood HACCP

rule, FDA used an assumption that the rule would prevent 50 percent of

the current number of annual enforcement actions. The agency did not

receive comments on this assumption in that rule and does not yet have

data from implementation of the rule to validate it. However, this may

be a conservative assumption. If HACCP plans are properly conceived,

implemented and validated, it is likely that the vast majority of

problems will be caught and corrected in the plant, rather than result

in foodborne disease outbreaks or be caught through Federal sampling of

the final product. Thus, the agency will continue to make this

assumption but requests comment on it.

1. Import Enforcement

Over the period 1992 through 1996, there were a number of imported

juice products detained for various violations of the Federal Food,

Drug, and Cosmetic Act (the act). A detention is a procedure for

preventing violative products from entering the United States.

Following a determination that a sample of a product is violative,

three steps occur: (1) FDA sends a detention notice to the importer

providing an opportunity to introduce testimony as to the condition of

the product; (2) the importer may contact an attorney, submits a

response application, and introduces evidence regarding the product;

and (3) FDA makes a determination about what should be done with the

shipment. There are three actions that FDA can specify for a detained

shipment: (1) The product is allowed to be ``reshipped'' out of the

country, (2) the product is reconditioned so as to bring it into

compliance with U.S. law, or (3) the product is destroyed under Federal

supervision. Assume that the cost per shipment of the three steps to

all parties involved is $5,000. Then the remaining cost of detention is

the cost per shipment of the three actions which is related to the

value of the shipment.

Table 1 gives the number of shipments detained and the total dollar

value of juice products detained for violations of the act for the

entire period 1992 through 1996.

The average value per shipment of imported juice products refused

entry is approximately $10,000. The average number of imported juice

product shipments detained annually is 23.

[[Page 24258]]

Table 1.--Totals of Juice Import Detentions for 1992 through 1996 by Reason for Detention

--------------------------------------------------------------------------------------------------------------------------------------------------------

Poisonous or Violative

Reason for Detention Food Additive Deleterious Pesticide Chemical New Drug Microbial Total

Issues Substances Residues Contamination Residues Hazards

--------------------------------------------------------------------------------------------------------------------------------------------------------

Number of Shipments 44 17 53 1 1 1 117

Value of Shipments $122,000 $112,000 $802,000 $79,000 $20,000 $2,000 $1,137,000

--------------------------------------------------------------------------------------------------------------------------------------------------------

If, on an annual basis, 23 imported juice product shipments are

detained at an average Federal enforcement and industry negotiation

cost of $5,000 per shipment (60 FR 65189), and if all 23 shipments

(with an average value of $10,000 per shipment) are destroyed so that

the entire $10,000 value of the shipment is lost, then the total annual

cost of all juice detentions is approximately $345,000 (23 shipments x

($10,000 value of shipment + $5,000 enforcement and negotiation cost)).

If 50 percent of these enforcement costs are prevented, then the

benefits related to import enforcement are approximately $175,000.

2. Recalls

Recalls tracked by FDA for pathogens or pesticides in juice

products are infrequent. For the period 1992 through 1996 there was one

class 1 recall and there were seven class 2 recalls\4\ for such

hazards, or about two recalls per year. A class 1 recall may cost as

much as $3 to $5 million between expenditures by the manufacturer,

retailers and State, local, and Federal authorities. However, the

typical juice recall is smaller and less costly than this. If the

combination of industry and government costs per recall on average is

$1 million, then the total annual cost of juice recalls is

approximately $2 million (2 recalls per year at $1 million each). This

assumption is based on FDA conversations with industry for both large

and small recalls. FDA acknowledges that this may not be the true

average cost of a recall and requests comment on this assumption. If 50

percent of these enforcement costs are prevented, then the benefits

related to recalls tracked by FDA are $1 million. However, FDA may not

be aware of all recalls that take place, particularly for less

hazardous reasons. Assuming that the recalls that FDA is not aware of

are considerably smaller, perhaps costing $100,000, and that FDA may

only hear about 10 percent of such recalls, then the total annual cost

of such recalls could be $1 million. If 50 percent of these enforcement

costs are prevented, then the benefits related to recalls not tracked

by FDA would be $500,000. Thus, the total annual benefits of the HACCP

rule related to recalls is estimated to be $1.5 million.

---------------------------------------------------------------------------

\4\Class 1 recalls are for dangerous or defective products that

predictably could cause serious health problems or death. Class 2

recalls are for products that might cause a temporary health

problem, or pose only a slight threat of a serious nature.

---------------------------------------------------------------------------

In addition to those benefits, when firms have recalls that are

made public they will generally suffer a loss of sales, at least

temporarily, from lost ``goodwill.'' This alone does not result in a

social cost but rather a social transfer as other firms will step

forward to capture sales lost from the recalling firm. However, in

addition to the resources invested in recalling the product, the

recalling firm may invest real resources in advertising to recapture

lost goodwill, a social cost. FDA cannot quantify this cost.

B. Health Benefits

This section presents quantitative estimates of health benefits

from this rule. This is accomplished by the following steps:

1. The most significant hazards in juice are described in terms of

severity and duration;

2. The hazards are described in terms of resulting health effects

and symptoms when they cause illness;

3. The health effects and symptoms are translated into consumer

utility losses;

4. The utility losses are translated into values in terms of lost

dollars (this gives the cost per case for every combination of level of

severity and for the specified duration for each hazard);

5. The average annual number of reported cases associated with

juice are distributed according to the percentages associated with each

level of severity;

6. The factors used to account for under reporting of foodborne

illness are estimated;

7. The reported cases are multiplied by the under reporting factors

to get the estimated average annual number of cases;

8. The percentages of each type of hazard expected to be prevented

by the proposal are listed; and

9. The total health benefits of the proposal are derived by

multiplying numbers 4, 7, and 8.

That is, TB = RC x CF x CR x V, where

TB = total health benefits in dollars,

RC = number of reported cases,

CF = under reporting correction factor,

CR = percent of cases reduced,

V = dollar value per case averted (medical costs + value of pain and

lost function).

1. Description of Microbial Hazards in Juice

Most of the significant health risks associated with juice products

are microbial. In the last 5 years the hazards associated with

commercially processed, packaged juice produced by nonretail

establishments include Bacillus cereus, Escherichia coli O157:H7, and

Salmonella non typhi.\5\ Table 2 lists these hazards with associated

severities and duration of severities. These hazards have been directly

linked to orange and apple juice products. However, all juices take

farm produce as an input; all use similar types of processing steps;

and all are distributed in similar ways. Therefore, although other

types of juices are less likely to be associated with foodborne disease

outbreaks primarily because consumption of orange and apple juice

greatly exceeds consumption of all other types of juice combined, all

juices are similarly vulnerable to microbial contamination. All juices

are sensitive to potential contamination by pathogenic microorganisms

due to the way fruits and vegetables are grown and harvested.

---------------------------------------------------------------------------

\5\ Most of the information in section V of this document

(Benefits) is taken from Ref. 9. It includes hazards other than

those for which benefits have been estimated in this analysis. The

hazards considered in section V of this document are those for which

the risk is highest. That is to say they are the most significant in

terms of probability of occurrence and severity.

---------------------------------------------------------------------------

Based on current scientific understanding, potential vehicles or

mechanisms for pathogenic cross contamination common to most fruit and

vegetable harvesting and juicing operations include water; manure

fertilizer; worker, field, and facility sanitation and transportation,

handling and processing. While most of the potential for contamination

would appear on the surface of the fruit or vegetable, the process of

juicing this

[[Page 24259]]

fruit or vegetable would potentially incorporate the pathogenic

microorganisms into the final juice product. Ref. 10, page 31, lists

the pH of some fruit and vegetable juices.

Table 2.--Description of Microbial Hazards in Juice

------------------------------------------------------------------------

Duration of

Hazard Severity Percent3 Illness (days)

------------------------------------------------------------------------

E. coli O157:H7

Mild 50 5

Moderate 32 9

Severe-acute 18 32

Severe- 2 26,645\1\

chronic

Death 1

Salmonella (non

typhi)

Mild 65 2

Moderate 30 5

Severe 5 17

Reactive 2 25

arthritis-

short term

Reactive 5 18,2502

arthritis-

long term

Death .1

B. cereus

Mild 99 .75

Moderate 1 1

Severe 0 NA

Death 0 NA

------------------------------------------------------------------------

\1\ Symptoms lasting 26,645 days, or 73 years, implies that it is

generally very young children who experience these severe chronic

effects (Ref. 2-3).

\2\Symptoms lasting 18,250 days, or 50 years. This estimate and other

information in section V of this document (Benefits) relating to

reactive arthritis are taken from Ref. 10.

\3\Percentages are taken from Ref. 10.

Symptoms of illness that results from exposure to each hazard may

be classified as mild, moderate, or severe. In general, mild cases are

not brought to the attention of a medical professional. Moderate cases

receive medical attention but do not require hospitalization. Severe

cases involve hospitalization and some of these result in death. The

``Percent'' column in Table 2 gives an estimate of the percentage of

the total number of cases that are classified in these four categories

of severity for each hazard. Note that the categories are not

necessarily mutually exclusive, for example, severe-chronic cases of E.

coli O157:H7 follow only after severe-acute cases of E. coli O157:H7,

and deaths follow only after severe cases. However, the ``Percent''

column reports each category of severity as a percentage of total cases

so that there is no double counting. Another factor that tends to

distinguish the categories of severity is the duration of time that

symptoms are experienced. The ``Duration'' column gives the general

duration of symptoms (in days) that are associated with the categories

of severity for each hazard.

2. Description of Health Effects and Symptoms of Microbial Hazards in

Juice

In order to quantify the loss (disutility) that individuals

experience from becoming ill, the pain, suffering, and mobility loss

must be scaled. Tables 3, 4, and 5 represent the outcome of one type of

scaling of these effects. Individuals who become ill experience

different levels of functional status in terms of mobility, ability to

do other physical activity, and ability to engage in social activities.

The ``Functional Status Code'' column in Table 3 represents the status

code which correlates with the categories of severity for each hazard.

Individuals who become ill also experience additional disutility due to

the symptoms of the illness. The ``Symptom/Problem Complex Code''

column represents the symptom/problem complex codes which correlate

with the categories of severity for each hazard. Descriptions of the

functional status and symptom/problem complex codes are given in Tables

4 and 5. FDA requests comment on this scaling model.

Table 3.--Description of Health Effects and Symptoms of Microbially Related Illnesses in Juice

----------------------------------------------------------------------------------------------------------------

Symptom/Problem Complex

Hazard Severity Functional Status Code1 Code2

----------------------------------------------------------------------------------------------------------------

E. coli O157:H7

Mild L20 8, 12, 13, 29

Moderate L19 8, 12, 13, 16, 19, 29,

32

Severe-acute (L1 x .2) + (L6 x 8, 12, 13, 16, 19, 29,

.8)\3\ 32

Severe-chronic L31 9

Salmonella (non typhi)

Mild L20 12, 13, 29

Moderate L20 12, 13, 29

Severe L6 12, 13, 16, 29

Reactive arthritis L35, L41, L42, L434 19

B. cereus

Mild L19 12, 13, 29

Moderate L19 12, 13, 29

[[Page 24260]]

Severe NA NA

----------------------------------------------------------------------------------------------------------------

\1\ Functional Status Codes are described in Table 4.

\2\ Symptom/Problem Complex Codes are described in Table 5.

\3\ The disutilities for two functional status codes were taken for severe cases of E. coli O157:H7 because

functional status varies among severe cases of this hazard.

\4\ Functional Status Code varies, Ref. 10.

In Table 4, the last column, ``Level of Disutility,'' represents

the degree of departure from perfect functionality. Thus, a person

would be functioning at about half capacity if the level was .5 and

would be even more diminished at .75. Code L42 is used whenever the

mobility, physical activity, and social activity conditions apply and a

person is experiencing a symptom described in Table 5. Code L43 is used

whenever the mobility, physical activity, and social activity

conditions apply and a person is experiencing no symptoms. In Table 5,

``Level of Disutility'' refers to the amount of pain and suffering such

that .03 would be minor pain and suffering relative to .3.

Table 4.--Description of Functional Status Codes1

------------------------------------------------------------------------

Function Status Physical Social Level of

Levels Mobility Activity Activity Disutility

------------------------------------------------------------------------

L1................ In special In bed or Had help .5626

care unit chair with

self-

care

L6................ In In bed or Had help .5301

hospital chair with

self-

care

L19............... In house Walked Performed .4176

with self-

physical care but

limitati not

ons work,

school,

or

housewor

k

L20............... In house Walked Limited .4448

with in work,

physical school,

limitati or

ons housewor

k

L23............... In house Walked Performed .3512

without self-

physical care,

limitati but not

ons work,

school,

or

housewor

k

L31............... Did not Walked Limited .4087

drive, without in work,

needed physical school,

help with limitati or

transport ons housewor

ation k

L35............... Drove car Walked Limited .3980

and used with in work,

transport physical school,

ation limitati or

without ons housewor

help k

L41............... Drove car Walked Did work, .3145

and used without school,

transport physical or

ation limitati housewor

without ons k, but

help other

activiti

es

limited

L42............... Drove car Walked Did work, .2567

and used without school,

transport physical or

ation limitati househol

without ons d, and

help other

activiti

es

L43............... Drove car Walked Did work, .0000

and used without school,

transport physical or

ation limitati househol

without ons d, and

help other

activiti

es

------------------------------------------------------------------------

\1\ Ref. 4.

Table 5.--Description of Symptom/Problem Complex Codes1

------------------------------------------------------------------------

Symptom/Problem Level of

Complex Description Disutility

------------------------------------------------------------------------

8................. Itching, bleeding or pain in

rectum .0379

9................. Pain in chest, stomach, side,

back, or hips .0382

12................ Sick or upset stomach, vomiting,

or diarrhea (watery bowel

movements) .0065

13................ Fever chills with aching all

over and vomiting or diarrhea .0722

16................ Headache, dizziness, or ringing

in ears .0131

19................ Pain, stiffness, numbness, or

discomfort of neck, hands,

feet, arms, legs ankles, or

several joints together .0344

29................ General tiredness, weakness, or

weight loss .0027

32................ Loss of consciousness such as

seizures (fits), fainting, or

coma (out cold or knocked out) .1507

------------------------------------------------------------------------

\1\ Ref. 4, p. D-14.

3. Utility Losses From Microbial Hazards in Juice

The ``Functional Status Code'' translates into values of disutility

given in the ``Functional Disutility'' column in Table 6. The symptom/

problem complex code translates into values of

disutility given in the ``Symptom/Problem Disutility'' column in Table

6. The ``Total Disutility'' column is the sum of the ``Functional

Disutility'' and the ``Symptom/Problem Disutility'' columns. The

``Utility Losses for Survivors'' column is derived by multiplying the

total disutility per day by the number of days that symptoms of the

illness persists. This gives the utility loss for survivors in terms of

the number of quality adjusted life days (QALD's) for each case of the

categories of severity for each hazard.\6\ FDA requests comment on this

estimation of utility loss.

---------------------------------------------------------------------------

\6\ A QALD is a day of perfect health.

[[Page 24261]]

Table 6.--Utility Losses From Microbial Hazards in Juice

----------------------------------------------------------------------------------------------------------------

Symptom/

Functional Problem Total Utility Losses

Hazard Severity Disutility Disutility Disutility for Survivors

(per day) (per day) (per day) (QALD's)

----------------------------------------------------------------------------------------------------------------

E. coli O157:H7

Mild .4448 .1193 .5641 2.8

Moderate .4176 .1668 .5844 5.3

Severe-acute .5464 .3175 .8639 27.8

Severe-chronic .4087 .0382 .4469 11,907.7

Salmonella (non typhi)

Mild .4448 .0814 .5262 1.1

Moderate .4448 .0814 .5262 2.6

Severe .5301 .0945 .6246 10.6

Reactive arthritis- .3980 .0344 .4324 10.8

short term

Reactive arthritis- .2582 .0280 .2862 5,223.2

long term

B. cereus

Mild .4176 .0814 .4990 .4

Moderate .4176 .0814 .4990 .5

Severe 0 0 0 0

----------------------------------------------------------------------------------------------------------------

4. Value of Losses From Microbial Hazards in Juice

FDA values a QALD at $630. This value derives from the statistical

estimate of a unit-risk reduction (commonly referred to as the value of

a statistical life (VSL)) which the Department of Health and Human

Services assigns the value of $5 million. Using $5 million for a full

lifetime yields a value for a quality adjusted life year (QALY) of

approximately $230,000, when discounted at 7 percent. (A QALY is the

estimated value of a year spent in perfect health. These values are

discounted to reflect time preferences for investments in health. That

is, as with any other commodity, people have a stronger preference for

good health now than they have for good health in the future. Costs or

benefits realized in the future are ``discounted'' to make them

comparable to today. Essentially, discounting is the inverse of the

interest rate. Thus, if a benefit of $1.10 were to be realized 1 year

in the future, this would be equivalent, at approximately a 10 percent

discount rate, to a benefit of $1 realized today. This is the reverse

of saying that $1 invested today at a 10 percent annual interest rate

is worth $1.10 1 year from now.) Dividing this value by 365 days per

year yields a value for a QALD of approximately $630. The ``Value of

Utility Losses for Survivors'' column in Table 7 comes from multiplying

the number of QALD's lost due to the illness (see ``Utility Losses for

Survivors'' in Table 6) by the value of a QALD, $630. This represents

the value of pain and mobility losses that individuals experience.

Additionally, there are the societal costs of medical treatment. These

costs are shared generally between insurance companies and individuals.

They include all aspects of medical expenses (e.g., physician visits,

laboratory tests, prescriptions and therapies, hospital stays). These

are estimated in the ``Medical Costs'' column in Table 7 (Ref. 2-3, pp.

19 and 40 and Ref. 10). The ``Value of Losses per Case'' column in

Table 7 is the sum of the ``Value of Utility Losses for Survivors''

column and the ``Medical Costs'' column for the categories of severity

for each hazard. FDA requests comment on these valuations.

Table 7.--Value of Losses From Microbial Hazards in Juice

----------------------------------------------------------------------------------------------------------------

Value of Utility

Losses for Value of Losses per

Hazard Severity Survivors Medical Costs Case (VSL=$5,000,000)

(QALD=$630) (QALD=$630)

----------------------------------------------------------------------------------------------------------------

E. coli O157:H7

Mild $1,800 $0\1\ $2,000

Moderate $3,300 $200\1\ $4,000

Severe-acute $17,200 $16,000\2\ $33,000

Severe-chronic $995,700 $225,000\3\ $1,221,000

Death NA NA $5,000,000

Salmonella (non typhi)

Mild $700 $200\4\ $1,000

Moderate $1,600 $800\4\ $2,000

Severe $6,700 $9,100\4\ $16,000

Reactive arthritis- $6,800 $1005 $7,000

short term

Reactive arthritis- $970,0005 $5,8605 $976,000

long term

Death NA NA $5,000,000

B. cereus

Mild $300 $0\6\ $300

Moderate $300 $100\6\ $400

Severe $0 $0 $0

[[Page 24262]]

Death NA NA $5,000,000

----------------------------------------------------------------------------------------------------------------

\1\ Ref. 2-3, p. 40.

\2\ Explained in Table 8.

\3\ Recalculated from data in Buzby et al., pp. 41-45 in order to arrive at the present value of the cost per

case using a 7 percent discount rate.

\4\ Buzby et al., pp. 18-19. Mild Salmonella medical costs are recalculated from data in Cohen, M. L. et al. so

as not to include productivity in medical costs.

\5\ Ref. 10.

\6\ The medical cost estimates for B. cereus were made by FDA for this analysis. The extremely brief duration of

mild cases suggests that there would be no medical costs for this level of severity. For moderate cases one

visit to a doctor with medical tests are estimated to cost approximately $100.

Table 8.--Medical Costs for Severe-Acute Cases Associated With E. coli O157:H71

----------------------------------------------------------------------------------------------------------------

Acute Hemorrhagic Average Severe-

Factors Colitis Acute HUS Acute Case

----------------------------------------------------------------------------------------------------------------

Percent of Severe Cases 80% 20%

Present Value per Case $11,000 $36,000

Weighted Present Value per Case $8,800 $7,200 $16,000

----------------------------------------------------------------------------------------------------------------

\1\ Ref. 2-3, p. 40.

5. Distribution of the Reported Cases per Year for Microbial Hazards in

Juice

Table 9 estimates the number of cases associated with each hazard

by severity. The ``Average Total No. of Cases Reported per Year''

column represents the average number of reported cases for each hazard

from 1992 through 1996. Cases for each hazard are divided among the

four categories of severity according to the percentages described in

Table 8. Only those reported cases associated with commercially-

produced juices sold in interstate commerce as beverages or used as

ingredients in beverages are included in the averages presented.

Table 9.--Distribution of the Reported Cases per Year for Microbial

Hazards in Juice

------------------------------------------------------------------------

Average No. of

Hazard Severity Percent Cases Reported per

Year

------------------------------------------------------------------------

Mild 50 8

Moderate 32 5

Severe-acute 18 3

Severe- 2 .3

chronic

Death 1 .2

E. coli O157:H7 Total cases 16\1\

Mild 65 8

Moderate 30 4

Severe 5 1

Reactive 2 .2

arthritis-

short term

Reactive 5 1

arthritis-

long term

Death .1 .01

Salmonella (non Total cases 12

typhi)

Mild 99 17

Moderate 1 .2

Severe 0 0

Death 0 0

B. cereus Total cases 17

------------------------------------------------------------------------

\1\ Total cases per pathogen are accurate. The sum of the number of

cases for all levels of severity per pathogen may not equal the total

number of cases per pathogen due to rounding.

6. Estimates of Factors Needed to Offset Underreporting of Foodborne

Illness

The cases reported in column 4 in Table 10 are the lower bound of

the likely total number of these cases. The total number of foodborne

illness is much greater than those numbers reported to the Centers for

Disease Control and Prevention (CDC) for several reasons. First,

individuals who become ill do not always go to doctors. This is

particularly true for milder cases of foodborne disease. Obviously, if

people do not go to health care professionals, the illnesses will not

be captured in any data base and will not be picked up by CDC. Second,

even when people go to health care professionals, they are not

necessarily diagnosed as having foodborne disease as the symptoms for

many types of

[[Page 24263]]

foodborne disease are common to influenza and other diseases. There is

often little incentive to culture stools to definitively identify a

pathogen if the disease is thought to be of short duration and not

requiring treatment. Even where a pathogen is identified, there is even

less incentive to identify the food or other vehicle which carried it.

Third, even when a correct diagnosis is made, State and local health

professionals do not always report these cases upwards, particularly

going as far as CDC. Again, milder cases are less likely to be reported

than more severe cases.\7\ To complicate matters, the rate of under

reporting is not observable, and, even if it were known in any 1 year,

it may fluctuate dramatically from year to year. Nevertheless, in order

to compensate for the rate of under reporting, the number of known

cases associated with a hazard (i.e., reported to CDC) is multiplied by

factors which are estimated to account for underreporting.

---------------------------------------------------------------------------

\7\ The CAST Report expands these three categories of reasons

that a case of illness may not be recognized as foodborne into six

reasons (Ref. 6).

---------------------------------------------------------------------------

In Foodborne Pathogens: Risks and Consequences (the CAST Report)

there are two estimates given of the actual number of foodborne

illnesses: One estimate made by Bennett et al., and one made by Todd

(Ref. 6, p. 46). Both Bennett et al. and Todd estimate the total number

of cases and the total number of deaths for each hazard. By dividing

Bennett's et al. and Todd's estimates of the actual number of cases and

deaths by the number of reported cases and deaths (Ref. 6, p. 42), the

respective implicit factors needed to correct for underreporting of

these categories for each hazard are derived. Based on these correction

factors, FDA has estimated correction factors for each category of

severity. The agency has taken the correction factor for the number of

cases as the correction factor for mild cases and the correction factor

for the number of deaths as the correction factor for severe cases. For

moderate cases, the agency has interpolated between the factors for

mild and severe cases. E. coli O157:H7 was not a recognized food-safety

hazard at the time that Bennett's et al. work was done. For a more

complete description of how these estimates were derived see the

Appendix attached to this document (Ref. 9).

In Table 10, the third column, ``Estimate of Underreporting

Correction Factor (Bennett),'' and the fifth column, ``Estimate of

Underreporting Correction Factor (FDA based on Todd),'' give the exact

implicit correction factors that can be derived from the work of

Bennett and Todd et al. The fourth column, ``Estimate of Underreporting

Correction Factor (FDA based on Bennett),'' and the sixth column,

``Estimate of Underreporting Correction Factor (FDA based on Todd),''

give FDA's interpolations of the work of Bennett and Todd et al. for

each of the identified categories of severity. In general, each

researcher's estimate of the underreporting correction factor for total

cases was used as the estimate for mild cases, and each researcher's

estimate of the underreporting correction factor for deaths was used as

the estimate for deaths and severe cases. FDA interpolated between each

researcher's estimates of underreporting for total cases and deaths to

derive under reporting rates for moderate cases. FDA requests comment

on these estimates of underreporting.

Table 10.--Estimates of Factors Needed to Offset Underreporting of Foodborne Illness

----------------------------------------------------------------------------------------------------------------

Estimate of

Estimate of Underreporting Estimate of Estimate of

Underreporting Correction Underreporting Underreporting

Hazard Severity Correction Factor (FDA Correction Correction

Factor based on Factor (Todd) Factor (FDA

(Bennett) Bennett) based on Todd)

----------------------------------------------------------------------------------------------------------------

Mild 195

Moderate 20

Severe 7

Death 7 7

E. coli O157:H7 Total cases ND\1\ 195

Mild 307 474

Moderate 307 45

Severe 246 4

Reactive arthritis- 307 474

short term

Reactive arthritis-long 307 474

term

Death 246 246 4 4

Salmonella (non typhi) Total cases 307 474

Mild 96 1,615

Moderate 96 1,615

Severe NA NA NA NA

Death NA NA NA NA

B. cereus Total cases 96 1,615

----------------------------------------------------------------------------------------------------------------

7. Estimates of Juice-Associated Cases per Year

In Table 11, FDA has estimated ranges of the likely annual number

of cases that occur for each of the four pathogens studied. The column

``Estimate of Actual No. of Juice Associated Cases per Year (FDA based

on Bennett)'' in Table 11 is derived by multiplying the ``Average Total

No. of Reported Cases per Year'' column in Table 9 by the ``Estimate of

Underreporting Correction Factor (FDA based on Bennett)'' column in

Table 11. The column ``Estimate of Actual No. of Juice Associated Cases

per Year (FDA based on Todd)'' in Table 11 is calculated in a similar

manner.

[[Page 24264]]

Table 11.--Estimates of Juice-Associated Cases per Year

----------------------------------------------------------------------------------------------------------------

Estimate of Estimate of Estimate of Actual Estimate of Actual

Underreporting Underreporting No. of Juice- No. of Juice-

Hazard Severity Correction Factor Correction Factor Associated Cases Associated Cases

(FDA based on (FDA based on per Year (FDA per Year (FDA

Bennett) Todd) based on Bennett) based on Todd)

----------------------------------------------------------------------------------------------------------------

Mild ND 195 ND 1,560

Moderate ND 20 ND 100

Severe-acute ND 7 ND 20

Severe-chronic ND 7 ND 2

Death ND 7 ND 1

E. coli O157:H7 Total cases ND 1,700

Mild 307 474 2,460 3,790

Moderate 307 45 1,230 180

Severe 246 4 150 2

Reactive 307 474 60 100

arthritis-

short term

Reactive 307 474 180 280

arthritis-long

term

Death 246 4 2 .04

Salmonella Total cases 3,800 4,000

(non typhi)

Mild 96 1,615 160 2,750

Moderate 96 1,615 2 30

Severe 0 0 0 0

Death 0 0 0 0

B. cereus Total cases 200 2,800

----------------------------------------------------------------------------------------------------------------

8. Percent of Cases Preventable by HACCP Proposal

In general, most pathogens will be eliminated when juice is heat-

treated. For example, E. coli O157:H7, and Salmonella should all be

completely eliminated from juice by standard methods of flash

pasteurization (absent extraordinarily high counts, detrimental human

intervention, or equipment failure). However, hazards associated with

B. cereus will not necessarily be eliminated by heat treatment. This

bacterium forms spores which are more difficult to kill by heat. After

heat treatment, if the spores survive, they may grow out and produce a

toxin which causes illness. Ideally, the best way to reduce illness

associated with B. cereus is by killing the bacterium in its nonspore

state before any toxin has been produced. For most types of heat-

treated juice, there is a small probability that the heat treatment

will take place when B. cereus is in its nonspore state. To the extent

that processors adopt controls for these hazards other than flash

pasteurization which are less effective, the percentage of cases

prevented may be smaller than those estimated here. FDA requests

comment on these estimates. Based on information from USAA, FDA

estimates that the exemption from the HACCP rule for retailers and

small retail processors will affect 14 percent of the volume of

unpasteurized juice. Therefore, the agency estimates that though

pathogen controls may be 100 percent effective in controlling some

hazards, such controls will only prevent 86 percent of the cases of

illness from these hazards.

Table 12.--Percent of Cases Preventable by HACCP Proposal

------------------------------------------------------------------------

Percent of Cases

Hazard Preventable by

HACCP Proposal

------------------------------------------------------------------------

E. coli O157:H7 86

Salmonella (non typhi) 86

B. cereus 9

------------------------------------------------------------------------

9. Estimates of Annual Benefits for HACCP Proposal

The total benefits for the categories of severity for each hazard

are derived by multiplying the percentage of cases preventable by the

HACCP proposal by the estimates of the number of actual cases. The sum

of those benefits for each hazard is the total benefits of the HACCP

proposal for pathogen control. Table 13 gives the estimate of benefits

for each hazard using each source of information on the appropriate

correction factor for underreporting.

Table 13.--Estimates of Annual Benefits for HACCP Proposal

------------------------------------------------------------------------

FDA Estimate of FDA Estimate of

Hazard Severity Annual Benefits Based Annual Benefits Based

on Bennett on Todd

------------------------------------------------------------------------

Mild $2,680,000

Moderate $360,000

Severe- $660,000

acute

Severe- $2,442,000

chronic

Death $5,000,000

E. coli O157:H7 Total $11,142,000

Mild $2,120,000 $3,260,000

[[Page 24265]]

Moderate $2,120,000 $300,000

Severe $2,080,000 $32,000

Reactive $350,000 $630,000

arthriti

s-short

term

Reactive $146,400,000 $234,240,000

arthriti

s-long

term

Death $10,000,000 $200,000

Salmonella (non Total $163,070,000 $238,662,000

typhi)

Mild $42,000 $711,000

Moderate $1,000 $12,000

Severe 0 0

Death 0 0

B. cereus Total $43,000 $725,000

------------------------------------------------------------------------

Table 14 presents a range of estimates of annual benefits based on

the estimates in Table 13. The low and high estimates do not represent

lower and upper bounds of benefits, but only a range of potentially

likely estimates.

Table 14.--Range Estimates of Annual Microbially Related Benefits for

HACCP Proposal

------------------------------------------------------------------------

Low Estimate of Annual High Estimate of Annual

Hazard Benefits Benefits

------------------------------------------------------------------------

E. coli O157:H7 $11,142,000 $11,142,000

Salmonella (non

typhi)\1\ $163,070,000 $238,662,000

B. cereus\1\ $43,000 $725,000

Totals $174,000,000 $251,000,000

------------------------------------------------------------------------

\1\ Ranges for these two pathogens are taken from two different

estimates that exist in the public health literature. The estimates

for the other pathogen was made by FDA, alone.

10. Percent of Cases Preventable by Labeling Proposal

FDA does not have direct estimates of the effects of a warning

label on the incidence of illness from juice consumption. FDA

indirectly estimates the effects by estimating how warning labels will

change consumption, assuming that changes in the number of illnesses

are proportional to changes in consumption. FDA believes that the

labeling rule will cause a reduction in the consumption of

unpasteurized juice, but the size of the reduction is uncertain. As a

likely value, FDA estimates that consumption and illnesses will decline

by 5 percent in response to the warning label. The 5 percent reduction

is the estimated effect on cooking practices of the USDA meat safe

handling label, as found in a recent survey (Ref. 11). However, there

are some dissimilarities between the meat and juice labels, most

particularly that the juice label is targeted at sensitive consumers.

If, for example, parents redirect children away from nonheat-treated

juice, then consumption and illness will decline by 16 percent, which

is the proportion of apple cider consumed by children under the age of

6 (Ref. 12). This estimate embodies the assumptions that cider

consumption is a good proxy for unpasteurized juice consumption, and

that parents will not let their children consume unpasteurized juices.

11. Estimates of Annual Benefits for Labeling Proposal

Table 11 shows FDA's estimate that there are approximately 5,600

cases of foodborne illness associated with commercially processed,

package juice produced by nonretail establishments. In addition to

these cases, an average of 6 cases annually of Cryptosporidium parvum

have been associated with commercially processed, packaged juice

produced by retail establishments exempted from the HACCP rule. Table

15 shows the agency's estimate of the actual number of cases per year

by severity.

[[Page 24266]]

Table 15.--Estimates of Juice-Associated C. parvum Cases per Year

------------------------------------------------------------------------

Average No.

of Cases FDA Estimate of FDA Estimate of

Severity Reported Underreporting Actual No. of Juice-

per Year Correction Factor\1\ Associated Cases per

(1992-1996) Year

------------------------------------------------------------------------

Mild 5 100 500

Moderate 1 10 10

Severe .06 5 .3

Death .001 5 .005

Total 6 500

------------------------------------------------------------------------

\1\Because C. parvum was not a recognized food safety hazard at the time

that Bennett et al. and Todd's work was done, FDA has made its own

estimates of the factors needed to correct for underreporting of this

hazard.

Table 16 gives the agency's estimate of the value of the loss per

case of C. parvum.

[[Page 24267]]

Table 16.--Estimate of Value of Losses Associated with Case of C. parvum

--------------------------------------------------------------------------------------------------------------------------------------------------------

Symptom/ Value of

Duration of Function Problem Total Utility Losses Utility Losses Value of Losses per

Severity Percent Illness (in Status Code\1\ Complex Disutility for Survivors for Survivors Medical Costs Case (VSL=$5,000,000)

days) Code\2\ (per day) (QALD's) (QALD=$630) (QALD=$630)

--------------------------------------------------------------------------------------------------------------------------------------------------------

Mild 90 9 L41 12, 13, 29 .3959 3.6 2,300 $0\3\ $2,000

Moderate 9 17 L41 12, 13, 29 .3959 6.7 $4,200 $400\3\ $5,000

Severe 1 24 L6 12, 13, 29 .6115 14.7 $9,300 $8,300\4\ $18,000

Death .02 NA NA $5,000,000

--------------------------------------------------------------------------------------------------------------------------------------------------------

\1\Functional Status Codes are described in Table 4.

\2\Symptom/Problem Complex Codes are described in Table 5.

\3\Medical Costs for mild and moderate cases of C. parvum were calculated by multiplying the per day medical costs for E. coli 0157:H7 for these levels

of severity by the duration of illness of C. parvum. The symptoms of C. parvum for these levels of severity are similar to those of E. coli 0157:H7.

\4\Medical Costs for severe cases of C. parvum were calculated by multiplying the per day medical costs for severe cases of acute hemorrhagic colitis by

the duration of illness of C. parvum. The implicit assumption is that the medical costs for acute hemorrhagic colitis (bloody diarrhea) are equivalent

to the medical costs for watery diarrhea associated with C. parvum.

[[Page 24268]]

The labeling rule is expected to prevent some cases of foodborne

illness as people avoid juice that is labeled. Because B. cereus is, in

general, not disproportionately associated with minimally processed

juice, cases of B. cereus are not expected to be prevented by the

labeling. However, to the extent that the label is effective and to the

extent of the volume of juice that is labeled, the labeling rule will

reduce the number of cases associated with E. coli 0157:H7, Salmonella

and C. parvum.

Combining the estimates of the number of illnesses in Tables 11

and 15, the total number of estimated cases associated with minimally

processed juice for these 3 hazards is 6,100 per year associated with

consumption of the 70 million gallons of minimally processed juice

produced annually. FDA has estimated that 14 percent of minimally

processed juice (10 million gallons) will be exempt from the HACCP rule

but will be covered by the labeling rule. Therefore, the number of

illnesses that may be associated with this volume of juice (10 million

gallons) will be exempt from the HACCP rule but will be covered by the

labeling rule. Therefore, the number of illnesses which may be

associated with this volume of juice (10 million gallons) is

approximately 900 and 5,200 illnesses are associated with minimally

processed juice covered by the HACCP rule.

As stated earlier, FDA estimates that consumption of labeled,

minimally processed juice will decline by 5 percent in response to the

warning label. This leads to the conclusion that the labeling rule is

expected to prevent approximately 50 illnesses annually (900 x .05). If

juice consumption decreases by as much as 16 percent in response to the

warning label, then the labeling rule may prevent as many as 140

illnesses per year.

The value of this reduction in illness depends on the type of cases

prevented. FDA assumes that these cases will be distributed according

to the share of illnesses associated with each of these hazards. Table

17 shows the expected distribution of cases prevented by labeling

across the hazards and severities.

[[Page 24269]]

Table 17.--Distribution of Cases Prevented by Labeling Proposal

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Low Estimate of High Estimate of Low Estimate of No. High Estimate of No. Low Estimate of No. High Estimate of No.

Actual No. of Juice- Actual No. of Juice- of Cases Prevented by of Cases Prevented by of Cases Prevented by of Cases Prevented by

Hazard Severity Associated Cases per Associated Cases per a 5% Consumer a 5% Consumer a 16% Consumer a 16% Consumer

Year Year Response to Labeling Response to Labeling Response to Labeling Response to Labeling

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mild 1,560 1,560 13 13 36 35

Moderate 100 100 1 1 2 2

Severe-acute 20 20 .2 .2 .5 .5

Severe-chronic 2 2 .02 .02 .05 .05

Death 1 1 .008 .008 .02 .02

E. coli 0157:H7 Total 1,700 1,700 14 14 39 38

Mild 2,460 3,790 20 31 58 87

Moderate 1,230 180 10 1 29 4

Severe 150 2 1 .02 4 .05

Reactive arthritis-short term 60 100 .5 .8 1 2

Reactive arthritis-long term 180 280 1 2 4 6

Death 2 .04 .02 .0003 .05 .0009

Salmonella (non typhi) Total 3,800 4,000 32 32 90 91

Mild 500 500 4 4 11 11

Moderate 10 10 .08 .08 .2 .2

Severe .3 .3 .002 .002 .006 .006

Death .005 .005 .00004 .00004 .0001 .0001

C. parvum Total 500 500 4 4 11 11

Total 6,000 6,200 50 50 140 140

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[[Page 24270]]

Table 18.--Value of Losses Prevented by the Labeling Proposal

--------------------------------------------------------------------------------------------------------------------------------------------------------

High Estimate of High Estimate of

Low Estimate of Value Value of Losses Low Estimate of Value Value of Losses

Hazard Severity of Losses Prevented Prevented by a 5% of Losses Prevented Prevented by a 16%

by a 5% Consumer Consumer Response to by a 16% Consumer Consumer Response to

Response to Labeling Labeling Response to Labeling Labeling

--------------------------------------------------------------------------------------------------------------------------------------------------------

Mild 26,000 26,000 72,000 70,000

Moderate 4,000 4,000 8,000 8,000

Severe-acute 7,000 7,000 17,000 17,000

Severe-chronic 24,000 24,000 61,000 61,000

Death 40,000 40,000 100,000 100,000

E. coli 0157:H7 Total 101,000 101,000 258,000 258,000

Mild 20,000 31,000 58,000 87,000

Moderate 20,000 2,000 58,000 8,000

Severe 16,000 300 64,000 1,000

Reactive arthritis-short term 4,000 6,000 7,000 14,000

Reactive arthritis-long term 976,000 1,952,000 3,904,000 5,856,000

Death 100,000 2,000 250,000 5,000

Salmonella (non typhi) Total 1,136,000 1,993,000 4,341,000 5,971,000

Mild 8,000 8,000 22,000 22,000

Moderate 400 400 1,000 1,000

Severe 0 0 100 100

Death 200 200 500 500

C. parvum Total 9,000 9,000 24,000 24,000

Total 1,000,000 2,000,000 5,000,000 6,000,000

--------------------------------------------------------------------------------------------------------------------------------------------------------

12. Pesticide Residues

Tolerances for pesticides in foods are established by the

Environmental Protection Agency (EPA) and enforced by FDA. FDA collects

samples for both surveillance and compliance purposes. Since the

incidence of violative pesticide residues in fruit and vegetable juices

is relatively low, few compliance samples are taken.

This discussion pertains to surveillance samples of fruit and

vegetable juices from 1991 through 1997 (see Table 15). The lab

classification scheme used for pesticide residues is:

1 = in compliance;

2 = not in compliance, but not of regulatory concern; and

3 = not in compliance, and of regulatory concern.

The class 2 and 3 violative sample data are summarized in Table 15.

Of the 1,196 surveillance samples of juice taken and analyzed during

this period, only three (approximately one quarter of one percent) were

class 3 violative. One was apple cider and the other two were apple

juice, and the violative pesticide residue was acephate in each case.

There were also five class 2 violations, in which trace quantities of a

pesticide with no tolerance (i.e., the pesticide was not approved for

use in the commodity) were found. The products with class 2 violations

were grape juice, watermelon juice concentrate, strawberry/nectarine

juice (2 samples), and apple juice concentrate; the pesticides were

chlorpyrifos, acephate, and methamidophos.

Pesticides present some potential chronic risks to humans at very

low levels of exposure. There is a small background risk associated

even with nonviolative pesticide residues and, in the case of products

with violative levels, an added risk from the violative residues.

(Violative residues are residues above tolerance or residues of

pesticides with no tolerance.)

Table 19.--Violative Pesticide Residues in Fruit and Vegetable Juices, 1991 through 1997

----------------------------------------------------------------------------------------------------------------

Commodity Fiscal Year Pesticide Amount Found, ppm Tolerance, ppm Class Violation

----------------------------------------------------------------------------------------------------------------

Grape juice 1993 Chlorpyrifos Trace None 2

Apple cider 1995 Acephate 0.075 None 3

Apple juice 1995 Acephate 0.052 None 3

Apple juice 1995 Acephate 0.040 None 3

Watermelon juice, 1995 Acephate Trace None 2

concentrate

Strawberry/ 1996 Methamidophos Trace None 2

nectarine juice

Strawberry/ 1996 Methamidophos Trace None 2

nectarine juice

Apple juice, 1997 Methamidophos Trace None 2

concentrate

----------------------------------------------------------------------------------------------------------------

There are two potential benefits associated with the regulation of

pesticides: (1) Decreases in cancer and other illness caused by chronic

consumption of pesticide residues and, (2) social benefits associated

with reductions in the costs of recapturing firm goodwill. The U.S. EPA

is responsible for determining the benefits of reducing exposure to

pesticide residues and, it is assumed, that the health benefits of the

enforcement actions proposed here are already accounted for when

regulatory tolerances are established. As to the

[[Page 24271]]

latter benefit, when firms have products with violative residues either

over tolerance for legal pesticides or any residue of an illegal

pesticide and a recall of the violative product becomes publicly known,

the sales of those firms are reduced, at least temporarily. Because

other firms will step in to supply the product, that loss of sales

alone does not constitute a social cost. However, it is likely that

real resources will be expended to recapture the lost ``goodwill'' that

would be in addition to the real expenditures made to actually recall

the product. FDA cannot quantify the cost savings that will occur

because of more vigilant monitoring of pesticide residues by firms

under a HACCP rule.

C. Other, Nonquantified Benefits

1. Firm Efficiency

The principle benefits from HACCP reported by the pilot firms are

more effective and efficient operations, a higher level of confidence

in the safety of the product, and greater customer satisfaction. The

pilot firms attributed these benefits to HACCP because of the following

results.

(1) Training makes the employees more aware of safety and needed

control measures, and empowers employees to prevent problems and

respond properly when deviations occur. Improvement in employee

performance was perhaps the most significant benefit from HACCP

expressed to FDA by the pilot firms. One firm reported that ``due to

increased HACCP awareness, employees have been instrumental in

designing new processes/procedures for monitoring and control.'' The

firm gave an example of a processing step that was changed to reduce

the likelihood of occurrence of a physical hazard. FDA is unable to

estimate the societal cost savings in terms of reduced product costs

which will, ultimately, affect the cost of implementing HACCP.

(2) SOP's and other documented procedures enable employees to

implement their tasks more consistently and effectively, and result in

smoother operations.

(3) Prerequisite programs and incoming ingredient controls prevent

hazards from being introduced into the process; continuous monitoring

reveals problems quickly and enables prompt correction and continuation

of production with less waste.

(4) Recordkeeping and review makes employees more accountable and

conscientious about safety.

(5) Validation and verification activities provide management with

greater control over their operations and documentation of the safety

of their product.

Perhaps the most significant benefit in terms of firm efficiency

will be cost savings from greater awareness by firms of violative

product runs, and the resulting increase in response to such violative

runs. Although the benefits of formal recalls have already been

accounted for, many pilot plant managers suggested that the continuous

monitoring required by HACCP enabled them to decrease the amount of

waste associated with production-line problems. For example, one

manufacturer noted that glass breakage was a constant problem on the

line and that, prior to HACCP, almost an entire lot would have to be

discarded because the manager could not be sure exactly when a problem

had started. With continuous HACCP monitoring, problems were caught

more quickly and the problem corrected more promptly, thereby

minimizing the amount of lost product.

The cost savings may be substantial from this source of benefits

but FDA is unable to quantify them. FDA requests comments on these and

other potential benefits.

2. Increased Shelf Life

Nonheat-treated juices have a limited shelf life. Heat-treated

juices have longer shelf lives. Depending upon temperature used,

increases of 7 days or more have been reported. Longer shelf life

allows more flexibility in the conditions of distribution and sale of

products. The agency requests comments on how this potential benefit

may be quantified.

D. Summary of Benefits

Table 20 summarizes the benefits of these two rules.

Table 20.--Benefits of Juice Proposals

------------------------------------------------------------------------

Type of Benefit Description Annual Value

------------------------------------------------------------------------

Enforcement: Reduced waste and Federal activity $175,000

Import from detaining violative juice

Detentions imports

Enforcement:Prod Reduced numbers of domestic recalls $1,500,000

uct Recalls of violative juice products

Health Benefits: Reduced illness and death from $174 to 251

HACCP controlling pathogens in juice million

Health Benefits: Reduced illness and death from $1 to $6 million

Labeling avoidance of minimally processed

juice

Health Benefits: Reduction of consumption of Not quantified

Pesticides violative pesticide residues in but small

juice and social losses from lost

goodwill

Other Benefits: Some offsetting reductions in Not quantified

Firm Efficiency manufacturing costs due to but potentially

increased worker productivity and large

less product waste

Other Benefits: Product Shelf life may be increased Not quantified

Increased Shelf for products achieving a 5-log but potentially

Life reduction of pathogens large

Total Quantified .................................... $180 to 260

Benefits million

------------------------------------------------------------------------

VI. Costs

A. General Industry Information Used Throughout This Analysis

The costs of these rules have been estimated by analyzing the costs

for each proposed requirement on a per-plant basis and multiplying

these costs by the number of plants affected by each requirement. Cost

per plant will vary by current practice, product, and size. In order to

determine the number of plants covered, the analysis will first analyze

coverage qualitatively.

1. Types of Plants Covered

The labeling rule and the HACCP rule do not equally affect an

identical subset of the food industry.

2. HACCP Rule Coverage

For the purpose of this rule, FDA has tentatively decided that

retailers will include processors who are very small businesses and who

make juice on their premises and directly sell juice or juice products

to consumers and other retailers provided that retail sales of juice

and juice products do not exceed 40,000 gallons per year. The HACCP

rule covers all processors of juice except those who are retailers.

Retailers may include grocery stores, supermarkets, farms, roadside

stands, restaurants and eating places.

[[Page 24272]]

3. Labeling Rule Coverage

The labeling rule covers processors and retailers of packaged

minimally processed juice. The labeling rule is also applicable to

packaged beverages that have not received further processing to control

microbial hazards and that contain minimally processed juice. Such

beverages include diluted juice beverages, ``smoothies,'' sports

drinks, flavored bottled waters, and carbonated beverages that contain

juice that was not processed to control pathogens.

Table 21 provides examples of the types of products and processors

covered and not covered by the two rules.

Table 21.--Coverage of Juice Proposals

------------------------------------------------------------------------

Covered by Covered by

Processor Type Labeling Rule HACCP Rule\3\

------------------------------------------------------------------------

Processors of packaged beverages sold as Yes Yes

juice\1\

Processors of packaged purees sold as Yes Yes

juice

Processors of juice used as an Yes Yes

ingredient in a beverage (e.g., the

cranberry juice in cranberry juice

cocktail)

Processors of juice which retail the Yes Yes

juice at a different location from

which it is produced

Processors of beverage concentrates sold Yes Yes

as juice

Processors of beverage bases of a fruit Yes Yes

origin or other beverage bases

including dried or powdered juice

mixes\2\

Processors of packaged baby (infant and Yes Yes

junior) fruit juices and drinks

Processors of juice that ship to a Yes Yes

different location (e.g., the juice

processing plant owned by a supermarket

chain that then ships the juice to the

chain's stores or very small processors

that sell juice from their own roadside

stand and to other retailers)

Retailers of packaged juice processed by Yes No

other establishments (e.g.,

supermarkets, restaurants and roadside

stands that sell juice produced by

another processor) Note: the juice sold

by these retailers is covered by the

HACCP rule but the retailer is not

covered by the HACCP rule.

Processors of packaged juice that do not Yes No

ship juice to different locations but

retail the entire production on the

premises (e.g., supermarkets, and

roadside stands that produce juice at

the point of sale)

Processors of beverages that include Yes No

juice as an ingredient but which do not

produce the juice itself

Retailers of juice processed for No No

immediate consumption

Processors of non-beverage products that No No

include juice as an ingredient

Processors of hard cider or other No No

alcoholic beverages

Processors of oils No No

Processors of purees not sold as No No

beverages (e.g., tomato puree)

Processors of juices not sold as No No

beverages (e.g., vinegar or borscht)

Processors of imitation juice flavorings No No

Processors of coffees, teas, or cocoa No No

products

------------------------------------------------------------------------

\1\ Juice types are berry; citrus; core fruit; mixed fruit; pit fruit;

subtropical and tropical fruit; vine fruit; other fruit; beans, peas

and corn; fruits used as vegetables; leaf and stem vegetables; mixed

vegetables; root and tuber vegetables; and other vegetables.

\2\ Beverage bases of fruit origin are berry, citrus, core fruit, mixed

fruit, pit fruit, subtropical and tropical fruit, vine fruit, and

other fruit.

\3\ A ``yes'' in this column applies only to processors producing in

excess of 40,000 gallons of packaged juice per year. Very small

businesses processing packaged juice, producing 40,000 gallons of

juice or less annually are classified as retailers for the purpose of

the HACCP rule and are therefore exempt from it.

4. Number of Establishments Covered

FDA's own Official Establishment Inventory (OEI, FDA's list of food

establishments under its jurisdication) lists approximately 900 juice

manufacturers. However, recent information from the U.S. Apple

Association (USAA) indicates that there are about 1,800 apple juice

plants, most of which are very small processors. A typical description

of these very small processors is an apple grower who operates a small

apple press and bottling operation on the same property. In general

these processors market their products in more than one way. The

channels of distribution include: Roadside stands owned by the

processors and stands owned by others, farmers' markets, grocery

stores, and restaurants. FDA has proposed to exempt retail

establishments from the HACCP rule. For the purposes of this rule, the

agency has tentatively decided that retailers will include very small

businesses that make juice on their premises and whose total sales of

juice and juice products do not exceed 40,000 gallons per year and who

sell directly to consumers or directly to consumers and other

retailers. Based on data supplied by the USAA, this exemption would

exempt from the HACCP rule 80 percent of apple juice processors. (Ref.

13). Such an exemption would leave approximately 360 apple juice

processors covered by both of these regulations, and all 1,800 would be

covered by the labeling rule.

The OEI lists about 200 plants in the United States that produce

core fruit (apple, crab apple, pear, quince, etc.) juice. If all of the

200 core fruit plants in the OEI are included in the USAA list and are

not exempt, then there would still be an excess of 160 apple juice

processing plants in the USAA list not exempt from the HACCP rule and

an excess of 1,600 (1,800-2000) plants in the USAA list not exempt from

the labeling rule. (Information from FDA's field inspections indicates

that very few of these 160 plants will be exempted from the HACCP rule

under the exemption for retailers of juice for immediate consumption.

Almost none of the very small apple juice processing plants recently

inspected by FDA retailed all of the juice that they produced at the

same location that it was processed. See Table 21 for a description of

the types of products and processors not covered.)

The agency is aware that there are also many very small orange

juice processors who grow oranges and who also operate a juicing and

bottling operation on the same property. However, the agency has no

direct information on the number of such orange juice processors. The

OEI lists about 300 plants in the United States that produce citrus

fruit juice. In this analysis, the agency has assumed that there is an

equivalent number (300) of very small processors who are not listed in

the OEI. It is likely that the proportion of very small orange juice

[[Page 24273]]

processors to OEI citrus juice makers is lower than the proportion of

very small apple juice processors to OEI apple juice makers because the

growing region for oranges in the United States is far smaller than the

region for growing apples.

FDA assumes for the purpose of this analysis, that 80 percent of

these very small orange juice processors will be exempt from the HACCP

rule based on their classification as retail establishments. This would

leave 60 very small orange juice processors covered by both of these

regulations, and all 300 covered by the labeling rule. FDA has assumed

that there are no vegetable juice processors which are not in the OEI

or which are not also very small processors of apple or orange juice as

estimated above. FDA requests comments on these assumptions.

FDA has assumed that 5 percent (about 50 plants (900 x .05)) of all

juice plants in the OEI would have implemented HACCP substantially in

the form required by this regulation by the time that this proposed

HACCP rule is finalized regardless of this regulatory action.

Therefore, approximately a total of 1,070 plants (850 plants in the OEI

plus 60 very small orange and 160 apple juice retailers) will be

affected by the HACCP rule.

The labeling rule will cover retailers (roadside stands and grocery

stores) of packaged minimally processed juice.

The agency does not have direct information on the number of

supermarkets and grocery stores that produce and package at the point

of sale and sell minimally processed juice. The agency believes that

only a portion of chain supermarkets and grocery stores do so. Duns

Market Identifier (DMI) lists approximately 9,400 chain supermarkets

(SIC 54110101) and approximately 3,800 chain grocery stores (SIC

54119904) making a total of approximately 13,000 chain supermarkets and

grocery stores. If 10 percent of these stores produce at the point of

sale and sell packaged minimally processed juice, then approximately

1,300 chain grocery stores and supermarkets will be affected by the

labeling rule. (In addition to these processors, there are other

retailers that do not process juice but which offer for sale the juice

produced by other processors, which should be labeled by the

manufacturer.)

Due to publicity about the hazards associated with minimally

processed juice, the agency believes that relatively few retailers are

offering such products for sale. DMI lists approximately 3,100

independent supermarkets (SIC 54110103) and approximately 31,000

independent grocery stores (SIC 54119905) making a total of

approximately 34,100 chain supermarkets and grocery stores. If 5

percent of these stores sell minimally processed packaged juice, then

approximately 1,700 independent grocery stores and supermarkets will be

affected by the labeling rule. The labeling rule will also affect

roadside markets and stands that retail packaged minimally processed

juice. For the purpose of this analysis, the agency assumes that there

are 1,000 such roadside markets and stands. However, the assumptions

that go into these calculations may be incorrect, and the agency

specifically requests comments on them.

Table 22 shows the estimated number of establishments affected by

each rule.

Table 22.--Number of Plants Affected by the HACCP and Labeling Rules

------------------------------------------------------------------------

No. of No. of

Establishments Establishments

Plant Type Affected by HACCP Affected by

Rule Labeling Rule

------------------------------------------------------------------------

Juice manufacturers in the OEI 850 201

Very small apple juice makers 160 1,600

Very small orange juice makers 60 300

Roadside retailers 1,000

Grocery stores and supermarkets

processing and packaging at the

point of sale 1,300

Total 1,070 4,220

------------------------------------------------------------------------

\1\ The number of juice manufacturers listed in the OEI affected by the

labeling rule is small (20) because most of these manufacturers are

already achieving a 5-log reduction. See Table 24.

5. Hourly Price of Labor

Throughout this analysis the hourly price of labor is taken to be

approximately $13. This is estimated by taking the 1996 average hourly

rural wage of $9.20 (Ref. 7) and increasing it by 40 percent (the

average amount for benefit costs paid by employers) (Ref. 8), or $3.70

to account for such costs in addition to wages, such as Social

Security, workers' compensation, unemployment insurance, paid leave,

retirement and savings, health insurance, and supplemental pay.

6. Length of Production Period

The agency is aware that many juice processors operate on a

seasonal basis. Information supplied by USAA indicates that 94 percent

of the apple cider producers process only seasonally. The season for

apple cider production runs primarily from September through December.

The other 6 percent operate year round. Many other processors covered

by the proposed HACCP rule (e.g., makers of beverage bases) may process

year round. The agency has assumed that 50 percent of the 850 plants in

the OEI plus all of the 220 very small juice makers affected by the

HACCP rule produce seasonally. Table 23 shows the length of the

production period for plants producing seasonally and year round.

Table 23.--Plants' Production Period

----------------------------------------------------------------------------------------------------------------

Weeks of Operation Hours of Operation

Production per Year per Day No. of Plants

----------------------------------------------------------------------------------------------------------------

Seasonal 16 12 645

Year Round 52 24 425

Total 1,070

----------------------------------------------------------------------------------------------------------------

[[Page 24274]]

B. Cost Estimates by Requirement

1. Costs have been estimated for the following sections of the

labeling regulation:

(1) Signs or Placards (Sec. 101.17(f)(3)(i) (part 101 (21 CFR part

101))

(2) Container Labels (Sec. 101.17(f)(3)(ii))

2. Costs have been estimated for the following sections of the

HACCP regulation:

(1) CGMP's (Sec. 120.5 (part 120 (21 CFR part 120))

(2) Prerequisite Program SOP's (Sec. 120.6)

(3) Hazard Analysis and HACCP Plan (Secs. 120.7 and 120.8)

(4) Corrective Actions (Sec. 120.10)

(5) Validation and Verification (Sec. 120.11)

(6) Records (Sec. 120.12)

(7) Training (Sec. 120.13)

(8) Imports and Foreign Processors (Sec. 120.14)

1. Labeling Costs

This cost depends strongly upon producers' responses to the

labeling requirements. Some producers may elect to comply early with

the HACCP rule and avoid the warning labels or labeling. Others may

choose to label until they are required to implement HACCP. Finally,

some firms may choose not to produce juice products because they

believe that either the cost of HACCP implementation or the negative

effect on revenue generated by consumer response to labels may depress

profits below a normal return for a substantial time period. Such

producers will be better served by reinvesting their capital into more

profitable ventures.

a. Signs or placards (Sec. 101.17(f)(3)(i)). The costs of signs and

placards may be estimated by multiplying the number of establishments

that must post placards by the cost per placard. As shown in Table 22

the agency estimates that the labeling rule covers approximately 4,220

plants. However, for the purpose of this analysis, the agency has

assumed that all those processors that will at some point be required

to implement HACCP will do so at the earliest possible date to avoid

the warning labeling, or delay operation until they implement a 5-log

pathogen reduction process.

The following analysis underlies this assumption. If displaying the

warning can be avoided by beginning pasteurization (or an equivalent 5-

log pathogen reduction process) sooner, some firms may marshal the

resources to do so. FDA does not have data, however, that will allow it

to predict how many firms will respond to this labeling regulation in

this fashion. However, one way to examine this choice is examine the

additional discounted costs of pasteurizing sooner. For example, if a

small firm's cost of initiating pasteurization is about $18,000, with

recurring costs of about $8,000, and the firm has an annual juice

revenue of $200,000, then a total sales decline caused by the warning

of 8 percent (a loss of approximately $16,000 discounted at a rate of 7

percent) or more spread over the course of 2 years (or approximately 4

percent for 2 years) would cause the firm to attempt to borrow the

funds needed to initiate pasteurization 2 years early or to delay

operation until it implements a 5-log pathogen reduction process. FDA's

predictions of consumer reactions to the labeling (for the purposes of

benefit estimations) are an expected loss of revenue of about 5

percent. Thus, there is a tentative conclusion that most firms that are

not exempt from the HACCP rule will choose to implement a 5 log

reduction in pathogens immediately rather than label and to delay

operation until such processes have been implemented.

However, there are many uncertainties contained in this simple

example. Because of the short time frame for labeling to begin, 60 days

from publication of the final rule, many firms may not be able to

purchase and install pasteurization equipment or find other means of

validating a 5 log reduction in the target organism. It is unclear how

manufacturers think that consumers will react to the warning signs,

they may believe that their customers will not reduce their purchases

of juice. Also, firms with larger sales or smaller pathogen reduction

costs will need a smaller percentage sales decline from labeling in

order to be induced to initiate 5 log pathogen controls early. Finally,

it is unclear how many firms will have immediate access to the capital

requirements imposed by this rule.

If, therefore, all processors which will eventually be covered by

the HACCP rule do not label, then they have no direct labeling cost.

The cost of the labeling rule to these processors is the extra expense

that results from implementing HACCP 2 years earlier than would be

required by the HACCP rule alone. This cost, as stated above, is

$16,000 (discounted for 2 years at 7 percent). Of the 1,070

establishments covered by the HACCP rule, all of the 20 firms in the

OEI which are also affected by the labeling rule (those estimated to be

producing minimally processed juice) plus all of the 220 very small

orange and apple juice processors covered by the HACCP rule are

affected in this way (240 plants in all). The agency assumes, based on

information from industry sources, that 30 percent of this set of

processors (72 plants) have already initiated or are in the process of

initiating pasteurization. Therefore, the total cost of the labeling

rule for this set of processors is $2,688,000 ($16,000 x 168 plants).

The establishments that will need to display warning labeling are

those 3,980 establishments covered by the labeling rule but not by the

HACCP rule. Based on information learned from FDA's nutrition labeling

rules, the average cost per placard (and periodic replacement) is

estimated to be $100. This estimate will encompass the possibility that

some firms may have to supply multiple signs to meet the requirement

that it will be available at the point of purchase. Therefore, the

total one-time cost for this set of processors is $398,000.

b. Container labels (Sec. 101.17(f)(3)(ii)). The cost of labeling

is estimated by multiplying the number of affected separable labels on

packaged products, normally referred to as stock keeping units (SKU's),

by the cost of changing the label to add the warning. Table 24 shows

FDA's estimate of the cost per SKU of placing a warning label on the

information panel for different lengths of the compliance period. These

costs decrease over time for several reasons. The primary reason is

that manufacturers change labels or, at least, reorder them at regular

intervals and a larger length of compliance period allows manufacturers

to incorporate regulatory changes into planned changes.

Table 24.--Label Change Costs per SKU for Different Lengths of the Compliance Period

--------------------------------------------------------------------------------------------------------------------------------------------------------

2 months 6 Months 1 Year 2 Years 3 Years

--------------------------------------------------------------------------------------------------------------------------------------------------------

Administrative costs $6,000 $1,800 $900 $450 $350

Redesign costs $1,500 $450 $450 $50 $50

Inventory loss $800 $250 $0 $0 $0

[[Page 24275]]

Totals $8,300 $2,500 $1,350 $500 $400

--------------------------------------------------------------------------------------------------------------------------------------------------------

Processors of minimally processed packaged juice which are not

covered by HACCP will need to add the warning to their package labels

at the end of the 2-year compliance period. FDA estimates that 2,980

processors will be subject to this provision (1,440 very small apple

juice retailers and 240 very small orange juice retailers exempted from

the HACCP rule plus 1,300 grocery stores producing packaged juice). The

total cost for this provision is $1,490,000 (2,980 x $500) at the end

of the 2-year compliance period. For simplicity of reporting and

calculation with the other labeling costs, this cost will be added as

$1,301,000 (the present value of $1,490,000 discounted 2 years at 7

percent).

c. Summary of likely labeling costs. The agency estimates that the

likely total cost of the labeling rule is a one-time cost of $4,387,000

($2,688,000 + $398,000 + $1,301,000).

2. HACCP Costs

a. CGMP's (Sec. 120.5). This section of the proposal reaffirms the

applicability of the CGMP's in part 110 in determining whether facility

design, materials, personnel practices, and cleaning and sanitation

procedures are safe.

No costs are attributed to this section for this rulemaking. The

overwhelming majority of juice plants are in compliance with the

CGMP's. In 1996 only 6 percent of the plants inspected were cited for

official action. Therefore it is assumed that these rules will not have

any effect on the enforcement of the CGMP's for juice products.

b. Prerequisite program SOP's (Sec. 120.6). FDA is proposing to

require that processors control and document specific SOP's that

provide a foundation for the HACCP system and to have and implement

SOP's for prerequisite programs. In general, there are three activities

that are part of prerequisite program SOP's: (1) Developing SOP's, (2)

implementing sanitation controls with corrections of deviations from

SOP's, and (3) monitoring and documenting for SOP's.

i. Developing SOP's. Each processor must have a sanitation SOP. FDA

estimates that SOP's for juice plants could be developed with 20 hours

of labor. At the rural hourly cost of labor ($13), the cost per plant

of developing SOP's is approximately $260. If one half of the 900

domestic plants in the OEI and all of the 220 very small juice

processors do not currently have SOP's, then they will have to develop

them to comply with this regulation, if it is adopted. Under those

assumptions, the total cost for the industry to develop SOP's would be

approximately $174,200 ($260 x 670 plants).

ii. Implementing sanitation controls with corrections of deviations

from SOP's. Each processor must implement a sanitation SOP and correct

deviations from the prerequisite program SOP's in a timely fashion.

In 1996, 39 percent of the juice plants inspected were cited as VAI

(voluntary action indicated). This citation usually indicates that an

investigator noted deficiencies that were not significant enough to

warrant an administrative or regulatory action but which should be

corrected on a voluntary basis. Information from the inspection reports

indicates that approximately 30 percent of the juice plants inspected

had sanitation and food safety related deficiencies, 4 percent had

deficiencies which were related to low-acid canned food regulations,

and 4 percent had deficiencies for misbranding or mislabeling. Also in

1996, 6 percent of the juice plants inspected were cited as OAI

(official action indicated). This citation indicates that an

investigator noted deficiencies significant enough to recommend

regulatory or administrative sanctions. Information from the inspection

reports indicates that 3 percent of the juice plants had significant

deficiencies that could be related to food safety or low-acid canned

food regulations, 2 percent had significant deficiencies for

misbranding or mislabeling.

On a few of the VAI inspection reports, FDA investigators indicated

an estimate of the cost of correcting sanitation and food safety

related deficiencies indicated. Two-thirds of the reports estimated

costs of corrections at $0 to $99, and one-third of the reports

estimated costs of corrections at $1,000 to $4,999.\8\ Taking the

middle of these ranges gives an average estimated cost of corrections

of approximately $1,000 (($50 x 67 percent) + ($3,000 x 33 percent))

per plant for correcting sanitation and food safety related

deficiencies.

---------------------------------------------------------------------------

\8\ No reports estimated costs of $100 to $999.

---------------------------------------------------------------------------

The HACCP rule will mandate the implementation of daily monitoring

of sanitation controls. This should make the correction of sanitation

and food safety related deficiencies happen on the day that they occur

rather than months later. Regulatory inspections of juice plants are

made approximately once every 5 years. If food safety and sanitation

related deficiencies occur on average approximately once every 5 years

midway between inspections (to facilitate calculation), then the HACCP

rule should cause corrections to be taken an average of 2.5 years

earlier than would be the case without the rule. The cost of the rule,

then, is not the full cost of taking the corrections. Those corrections

would be taken even without the HACCP rule after the plant was

inspected and the deficiencies noted. The cost of the HACCP rule is the

present value of making the expenditures to correct the deficiencies at

an earlier date than would take place otherwise. The present value of

making an infinite series of $1,000 expenditures once every 5 years and

2.5 years earlier than they would otherwise occur is $500 when

discounted at 7 percent.

Based on information from inspection reports, FDA assumes that

about 30 percent of all 1,070 covered juice plants (about 320 plants)

are not likely to have sanitation controls that are sufficiently

implemented, but which do not warrant administrative or regulatory

action. If it costs each of these 320 plants $500 to implement

sanitation controls and to correct deviations from SOP's, then the

total cost borne by the industry for this requirement is $160,000,

which, because it is discounted, will be added as a one-time

expenditure in the total costs.

iii. Monitoring and documenting of SOP's. All procedures in the

prerequisite program SOP's are required to be conducted at the

frequencies specified and implementation of these procedures will have

to be monitored and documented.

FDA estimates that monitoring and documenting of SOP's will require

one-half hour of labor per operating week. The cost per plant of SOP

monitoring and documenting is given in Table 25.

[[Page 24276]]

Table 25.--Annual Per Plant Cost of SOP Monitoring and Documenting

----------------------------------------------------------------------------------------------------------------

Estimate Hrs. per Estimate Annual

Weeks of Operation Week for SOP SOP Monitoring and

Production per Year Monitoring and Wage ($/hour) Documenting Cost

Documenting per Plant

----------------------------------------------------------------------------------------------------------------

Seasonal 16 .5 $13 $100

Year round 52 .5 $13 $340

----------------------------------------------------------------------------------------------------------------

Table 26 shows the distribution of per plant and total industry

costs based on the estimate in Table 25 for SOP monitoring and

documenting needed to comply with this rule, if it is adopted. These

estimates assume that no plants are currently in compliance with these

particular requirements.

Table 26.--Total Annual Cost of SOP Monitoring and Documenting

----------------------------------------------------------------------------------------------------------------

Estimate Annual

SOP Monitoring and Estimate Annual

Production Documenting Cost No. of Plants SOP Monitoring and

per Plant Documenting

----------------------------------------------------------------------------------------------------------------

Seasonal $100 645 $64,500

Year round $340 450 $153,000

Totals 1,095 $218,000

----------------------------------------------------------------------------------------------------------------

c. Hazard Analysis and HACCP Plan (Secs. 120.7 and 120.8). Under

the proposal, processors are required to have a written hazard analysis

and to have and implement a written HACCP plan whenever a hazard

analysis reveals a food hazard that is reasonably likely to occur.

Requirements are set forth for the minimum contents of the plan and for

the signing and dating of the HACCP plan by specified personnel.

Failure of a processor to have and implement a HACCP system in

compliance with this rule, if adopted, will render the food products of

that processor adulterated.

i. Hazard analysis and HACCP plan development. Under the proposal,

each plant is responsible for developing a written hazard analysis of

hazards that are reasonably likely to occur in the product that a

processor can control. The hazards to be considered are any chemical,

physical, and biological hazards that may cause illness, injury, or

death in humans. Plant management must determine the likelihood of

occurrence of these hazards, either due to their introduction through

material inputs or processing or a possible failure to eliminate them

or to reduce them to acceptable levels in processing. Some Federal

Government sampling and illness outbreak data are available to provide

firms with a set of possible hazards that may affect a particular

product and process. In addition, section V of this document, the

accompanying appendix, and the preambles to these proposed rules

contain information on most of the hazards that have caused problems in

juice products in the past. Additional information may be forthcoming

in the HACCP final rule (after FDA evaluates the comments). Experience

from the HACCP pilot suggests that the hazard analysis for products

similar to juice took 16 to 24 hours. FDA's preliminary estimate is

that it will take approximately four individuals, including a plant

manager; 5 hours each to complete the hazard analysis; and another 15

hours each to formulate the HACCP plan. The HACCP plan requires that

the plant manager, quality control official and others establish

critical control points (CCP's) for every hazard identified in the

hazard analysis and critical limits at each CCP; establish a plan to

monitor those CCP's; determine how deviations from critical limits will

be handled; and establish procedures for verification and validation

that the plan is being followed and that it is properly controlling the

identified hazards. FDA assumes that part of this process will be to

determine the most cost-effective means to comply with this regulation

when developing the plan. Thus, the total number of person hours per

plant to develop both documents is 80 hours. At $13 per hour the total

cost per plant is about $1,000 per plant.

FDA has assumed that about 5 percent (50 plants) of all juice

plants in the OEI will have implemented HACCP substantially in the form

required by this regulation by the time that this regulation is

finalized regardless of this regulatory action. This assumption is

based on conversations with pilot plant firms who have indicated to FDA

that many large firms have begun both to do HACCP and require HACCP of

their suppliers. It is estimated that approximately 1,070 plants will

need to do hazard analyses and develop HACCP plans to comply with this

rule, if it is adopted. Therefore, the total cost of 1,070 plants at

$1,000 each to develop a hazard analysis and a HACCP plan is

approximately $1,070,000 million.

ii. Pesticide HACCP controls. Pesticides may be a component of

material inputs that must be controlled. If a processor has direct

knowledge of the amount of pesticide applied, either because the

produce is from the processor's own farm or because records showing the

application of pesticides accompanies the incoming produce, then the

processor may control pesticide hazards by means of a supplier

certificate. Under such an arrangement a supplier would only need to

provide the processor with a certification that any pesticides had been

properly applied to the produce so as not to exceed applicable

tolerances. As each arrives at the processing plant, a worker will need

to verify that the supplier for that shipment has supplied the

processor with a proper and up-to-date certification. FDA assumes that

verification of supplier certification requires 1 minute per shipment

which, at $13 per hour, represents a cost per shipment of approximately

$0.25.

FDA has estimated the number of shipments that will be verified in

this manner by working backward from the amount of juice consumed.

Annual juice consumption in the United States is 2.3 billion gallons

(gal). The agency assumes that 80 percent of this total (1.84 billion

gal) is produced by approximately 75 large firms (operating 225

plants). FDA believes that all large firms are currently doing a

sufficient

[[Page 24277]]

amount of sampling and monitoring (or receiving supplier certificates)

for pesticides. Therefore it is assumed that there are no costs for

large firms to comply with this requirement. That leaves 20 percent of

the total (460 million gal) produced by approximately 2,575 small and

very small firms. FDA assumes that all small and very small firms use

domestic produce only. If 15 pounds (lb) of produce are required to

make 1 gal of juice, then small firms use 6.9 billion lb of domestic

produce (460 million gal x 15 lb/gal). If 45,000 lb of produce (the

amount carried by a typical tractor trailer) constitutes 1 shipment of

produce, then small and very small firms use 153,000 shipments of

produce (6.9 billion lb 45,000 lb/shipment).

However, for the purposes of this proposed regulation FDA is

including as retailers very small businesses that make juice on their

premises, whose total sales of juice and juice products do not exceed

40,000 gallons per year and who sell directly to consumers or directly

to consumers and other retailers. This exemption decreases the

percentage of juice processed under pesticide controls by approximately

14 percent thereby reducing the number of shipments of produce to

132,000 (153,000 x 86 percent).

FDA assumes that 80 percent of small and very small firms covered

by the rule (676) will process shipments of produce that will be

accompanied by supplier certifications of pesticide application after

the HACCP rule is in place. Therefore, the number of shipments to be

handled under prerequisite program controls is 106,000 (132,000

shipments x 80 percent) per year. Thus, this analysis assumes that the

average small and very small plant receives approximately 160 (106,000

shipments 676 small plants) shipments per year. The total per

plant cost is about $40 (60 shipments x $0.25/shipment) for the 676

small and very small plants that can control this issue in this way.

Based on these calculations, the total marginal cost of this type of

control for pesticides is approximately $27,000 ($40 x 676 plants).

If such records cannot be obtained, different types of controls

need to be implemented. In this case, the processor must run pesticide

residue tests to ensure that there are no pesticides either over

tolerance or used on products for which there is no tolerance. To

determine the frequency of such testing, processors may avail

themselves of Government test results which indicate the likely

variance of illegal residues over a particular crop or region.

Current records indicate that, for domestic crops, only about .25

percent (one-quarter of 1 percent) are out of compliance. Furthermore,

as HACCP is adopted by more of the food industry, it is expected that

records, for some types of produce, will routinely accompany produce

intended for interstate commerce. However, many types of produce are

currently commingled at different stages in the distribution network.

This creates a problem for backtracking when there are either pesticide

or pathogen problems.

There are two potential costs associated with ensuring that

pesticide residues are legal: (1) Matching and shipping pesticide spray

records with crops and (2) costs of multiresidue testing. If records

are to accompany produce, fruits and vegetables may only be commingled

if all of the commingled produce has records showing it is under

tolerance. Otherwise, produce with paperwork must be kept separate from

produce without such paperwork. In the latter case, if it is to be used

to produce juice, multiresidue tests must be performed costing about

$150 per test. Just as was calculated for supplier certificates, FDA

calculates that there are 132,000 shipments which use 5,865 million

pounds of produce that must be covered by pesticide controls. As 80

percent has been considered to be handled by supplier certificates, 20

percent of the remaining shipments must be covered by a sampling plan.

Thus, of the 845 small plants total, 169 will cover an average of 160

shipments with a pesticide sampling plan. The number of shipments that

must be tested is about 26,000 (132,000 x 20 percent) per year.

Because of the likelihood of a very low violation rate,

approximately one-quarter of 1 percent, which is coupled with a maximum

upper bound added risk of about 1 in a million lifetime cancer cases

(see section V of this document), those processors who are unable to

obtain supplier certificates should need to only sample lots

periodically to ensure that such lots are in compliance. If the average

number of shipments per plant per year is 160, processors could

randomly sample 10 shipments per year and, assuming all were negative,

could be assured with 80 percent confidence that there are no more than

14 percent violative lots in the entire season's produce input.

Furthermore, if processors are turning up violative shipments, they are

expected to take corrective action to prevent future shipments from

being violative so that the rate of violative juice that reaches

consumers is expected to stay extremely low. Thus, costs will be

estimated for these processors based on 10 random samples per year at a

cost of $150 per sample. Based on these calculations, the total

marginal cost of pesticide testing is approximately $254,000 (10 tests

x $150/test x 169 firms). Costs per plant are estimated to be an

average of $1,500. Therefore, the total annual cost of pesticide

control for the HACCP rule is $281,000 ($254,000 for pesticide testing

+ $27,000 for supplier certificate verification).

iii. Pathogen HACCP controls. Processors will need to include

controls for microbial hazards in their HACCP plans and to implement

these controls in their operations. Potential microbial hazards include

both heat sensitive and heat resistant pathogens (and heat resistant

toxins produced by pathogens), including viruses. However, FDA is

interested in the safety of products as they are consumed, and any

combination of controls that successfully controls pathogens will

satisfy the requirements of this regulation. This regulation will allow

each processor to choose the combination of control measures that cost-

effectively controls microbial hazards. In addition, because of this

``performance'' nature of HACCP, manufacturers will be encouraged to

continue to seek out and implement less costly and more effective

methods.

Processors may attempt to control pathogens through other means,

using a combination of several steps that are less effective

separately, but which when used together will achieve adequate log

reductions of pathogens. These methods may include control of

contamination at the growing level, including use of potable water for

irrigation, use of safe fertilizers, rejection of fruits dropped from

trees onto the ground, and application of good sanitation practices

during harvesting. Other controls that can be applied at the receiving,

sorting, and processing levels include washing, brushing and sanitizing

the product before extraction, acidifying the product, and using

preservatives. FDA requests comments on potential costs and use of

these or any other methods.

At present, pasteurization is the primary effective, commercially

implemented method for controlling pathogens in juice. However, the

agency is not proposing to require pasteurization in the proposed HACCP

rule since other methods, either singularly or combined, may be as

effective in achieving the 5-log reduction. However, the effectiveness

and commercial feasibility of these other methods have not been

established over a significant period of

[[Page 24278]]

time. It is possible that the effectiveness and feasibility of other

methods will be established prior to the finalization of the HACCP

rule, thus affording processors a less expensive means of pathogen

control. To the extent that processors adopt other, less expensive

pathogen controls, the costs for pasteurization estimated in this

analysis will be an overestimate of the actual cost of the rule. The

agency has estimated an option for carrying out pasteurization that it

believes minimizes the cost of pasteurization. That is, the agency has

estimated the costs of purchasing special, low cost pasteurizers

designed for low-volume applications that are suited to small

businesses. It is also worth mentioning that pasteurized juice products

can be made using drops and culled produce, which significantly lowers

the cost of the material inputs. Processes other than pasteurization

may not be able to reduce pathogens sufficiently to accept this type of

produce.

Another possibility, for which FDA has not estimated costs, is that

processors that do not have pasteurizing equipment on site will ship

their juice to a facility that can provide them with pasteurization and

bottling service and then ship the bottled juice back for distribution.

Juice and dairy plants are the facilities most likely to be able to

provide this service. Purchasing the service of pasteurization may be a

more cost-effective option for some juice processors.

In fact, some juice companies do contract out their juice making

process. They blend the different varieties of raw produce for their

product and then ship it to a processor. There the produce is washed

and culled, pressed, pasteurized, bottled, and labeled. The juice is

then picked up by the owner and distributed. Other juice companies have

contracted out the pasteurization-bottling processes. They press the

produce themselves, then ship the juice to a pasteurization-bottling

facility to be pasteurized and bottled. Still other companies have

contracted out the pasteurization process only. They press the produce

themselves, then ship the juice to a pasteurization facility to be

pasteurized, and then ship the pasteurized juice back in bulk for

bottling and distribution. If some juice companies decide to take

approaches similar to these in response to this rule, their operations

will change fundamentally. Juice processors will choose the option

which will result in the lowest marginal cost to produce juice. The

agency has not included the estimate of the cost of contracting out

pasteurizing because of: (1) The increased complexity of the HACCP plan

to control for recontamination, (2) the problem of estimating

processors' access to pasteurization equipment owned by other

processors, and (3) the extra expense involved in transporting the

products. All these cast serious doubt on the feasibility of this

option for many very small processors. However, this analysis is

uncertain and FDA would expect each manufacturer to examine the option

of contracting their product to be pasteurized and taking advantage of

this where it is less costly than purchasing their own equipment.

Another aspect of pathogen control which some processors may adopt,

and for which FDA has not estimated costs, is juice refrigeration.

Pasteurized juice which has not been heated to the degree so as to make

it shelf stable must be refrigerated. This cost has not been

investigated because the agency has assumed that producers of nonshelf

stable juice are already refrigerating their products. The agency

requests comment on this assumption and on the cost of refrigeration,

if any, over and above that which is already being done.

The costs of pasteurization vary depending on numerous factors,

such as the capacity of the facility, and the amount of labor. In

addition, there is uncertainty in the estimates of the number and size

of the processors who will need to install pasteurization equipment,

among other factors. Some makers of cider processing equipment are

marketing pasteurization units for small processors. Medium sized

pasteurization/heater/chiller units are reported to cost about $17,000

plus about $1,500 for installation. These units have the capacity

necessary to meet the needs of a small processor producing about

400,000 gal of juice in a 4-month season.

Additionally, initial startup of pasteurization would require

alterations in plant construction, design or layout to accommodate the

additional processing step and equipment operator training. Also, there

are operating expenses related to pasteurization including utilities,

cleaning, maintenance and repair, and depreciation. Table 27 lists the

parameter values that have been used in a Monte Carlo analysis to model

the potential costs of installing and using pasteurization equipment by

juice processors.

Table 27.--Inputs and Results of Monte Carlo Analysis of Initiating Pasteurization

----------------------------------------------------------------------------------------------------------------

Parameter 10th Percentile Mean 90th Percentile

----------------------------------------------------------------------------------------------------------------

Wage rates $11.30 $13 $14.70

No. of operating months 2 6 9

Plant capacity (in gal) 34,000 74,000 124,000

Installation costs $1,300 $1,500 $1,700

Cleaning hours (monthly) 52 60 68

Costs of the pasteurizer $10,000 $17,000 25,000

Hours to operate (monthly) 26 30 34

Total Pasteurization Cost (per plant) $18,200 $26,200 $34,800

----------------------------------------------------------------------------------------------------------------

The key variables that affect this analysis are shown in the

``tornado'' diagram, Figure 1.

[[Page 24279]]

[GRAPHIC] [TIFF OMITTED] TP01MY98.000

For the purpose of this benefit-cost analysis, FDA has

preliminarily concluded that it is unlikely that fresh orange (and

possibly other citrus) juice processors will have to pasteurize their

products to achieve a 5-log reduction when a HACCP program is adopted

because of the nature of the fruits and the methods of juice extraction

commonly used by industry. Therefore, costs for these processors are

limited to the costs of creating and operating a HACCP system, not to

purchasing pasteurizing equipment.

Of the 1,070 processors covered by the HACCP rule only a portion of

these will need to initiate pasteurization. Table 28 shows FDA's

assumption about the number of processors in the OEI of various types

of juice that are not pasteurizing.

Table 28.--Types of Plants Currently Without Pasteurization

------------------------------------------------------------------------

No. Plants with Best Estimate of

Type Type as Primary Plants Minimally

Product Processing

------------------------------------------------------------------------

Berry 77 1

Citrus 211 10

Core 133 3

Mixed Fruit 36 1

Pit 31 1

Sub-tropical/tropical 29 1

Vine 2 0

Other 8 0

Beans/peas/corn 5 0

Fruits used as vegetables 41 1

Leaf/stem 8 0

Mixed vegetable 10 1

Root/tuber 8 1

Fruit beverage bases 37 0

Liquid fruit beverage bases 124 0

Combination true flavored and

imitation flavored beverages 19 0

Liquid combination true flavored

and imitation flavored

beverages 55 0

Other beverage bases 28 0

Baby (infant and junior) fruits,

juices and drinks 6 0

Totals 868 20

------------------------------------------------------------------------

Of the 20 processors in the OEI assumed not to be pasteurizing, 10

of these are citrus juice processors and may not need to initiate

additional controls beyond those already in place for controlling

pathogens. That leaves 10 processors in the OEI assumed to need to

initiate pasteurization. FDA's preliminary determination is that the 60

very small orange juice processors will not need to implement

additional controls for pathogens than those already in place. Of the

160 very small apple juice processors the agency assumes, based on

industry sources, that 30 percent (50)

This text is long and has been trimmed here. Open the source document for the complete record.

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.